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Regulatory T cells (Tregs) are required to maintain immune homeostasis through 
suppressive mechanisms. Characterized by the transcription factor Foxp3, they exert 
function in a variety of ways, including producing adenosine, and secreting suppressive 
cytokines. While mandatory for prevention of autoimmunity, Tregs contribute to cancer 
progression by suppressing the anti-tumor immune response. Depletion of the entire 
Treg pool is not a viable option for therapy, as mice and humans lacking this population 
succumb to systemic autoimmunity. Therefore, it is critical to uncover novel 
mechanisms to target Treg function specifically within the tumor microenvironment (TME) 
and determine means by which they can in turn be regulated or counter-regulated.  
Neuropilin-1 (Nrp1) is required to maintain Treg function and stability within the 
TME through binding of Semaphorin-4a, and when deleted from Tregs, mice show 
significantly reduced tumor growth or clearance (Appendix A). However, Nrp1 is 
dispensable for Treg function in the periphery, making this an attractive target in cancer 
immunotherapy. Interestingly, Nrp1–/– Tregs maintain Foxp3 expression but lose 
suppressive function, resulting in Treg ‘fragility’, a term I have coined to describe this 
phenomenon (Chapter 3). Rather, these cells secrete the pro-inflammatory cytokine 
IFNγ and cripple surrounding WT Tregs, leading to infectious fragility and enhanced anti-
tumor immunity. Strikingly, IFNγ-mediated Treg fragility is required for response to PD-1 
blockade in mice, and seems to be partially responsible for response to other 
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immunotherapies, including antibodies and vaccines (Chapter 4). Nrp1 also prevents 
Treg fragility by acting as a driver of Treg metabolic plasticity within the tumor 
microenvironment. Indeed, while WT Tregs are distinct metabolically in order to survive in 
a nutrient-depleted environment within the tumor, Nrp1–/– Tregs are dependent on 
glycolysis (Chapter 5). This is thought to be due to an increase in Hif1α which supports 
glycolysis and increases IFNγ in Tregs. Lastly, I have shown that Nrp1 supports Treg 
stability through maintaining hypomethylation at the Foxp3 locus in the tumor 
microenvironment, as Nrp1–/– Tregs are hypermethylated, but maintain Foxp3 expression 
(Appendix B).  
Taken together, my findings have uncovered new mechanisms that drive Treg 
fragility in tumors that are critical for response to immunotherapy. 
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1.0  INTRODUCTION 
Portions of this chapter (1.6 and 1.7) were compiled and submitted to Current Opinion in 
Immunology in the following manuscript: 
Overacre AE, Vignali, DA. “Treg stability: to be or not to be?” Curr Opin Immunol. 2016 
Jan 14;39:39-43. doi: 10/1016/j.coi.2015.12.009. 
1.1 CANCER  
1.1.1 Hallmarks 
Cancer is a chronic, often fatal group of diseases that can occur in a variety of tissues, 
each with a distinct microenvironment. It is the second leading cause of death globally 1 
and the single leading cause of death in those dying in the US under the age of 85. 
Cancer related deaths are expected to increase substantially over the next 2 decades. 
Cancer development occurs when normal cells are altered and take on a multitude of 
new ‘hallmarks’, including the ability to resist cell death, inducing angiogenesis, 
sustained proliferative signaling, evading growth suppressors, activating invasion and 
metastasis, and enabling replicative immortality. In addition, tumor cells can gain the 
ability to deregulate cellular energetics, enable genome instability and mutation, and 
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prevent immune clearance through avoiding immune-mediated destruction and 
promotion of ‘pro-tumor’ inflammation 2, 3.  
1.1.2 Cancer Immunoediting 
While traditional treatment methods (chemotherapy, surgery, radiation, hormonal 
therapy) are somewhat successful in a proportion of patients, many, primarily those with 
metastatic disease, are not responsive. This is thought to be in part due to the tumor’s 
ability to evade the immune system 4. Immunosurveillance, the process by which the 
immune system identifies and eliminates newly transformed cells that could be 
cancerous and is thought to be a major contributor of cancer prevention. IFNγ, whether 
produced naturally or administered exogenously, plays a critical role in 
immunosurveillance by acting directly on the tumor cells to induce autophagy, limit new 
protein production, promote antigen processing and presentation in the context of MHC 
molecules. It also acts on immune cells, leading to the production of chemokines that 
attract additional cells to the tumor site 5, 6, 7. While immunosurveillance is effective at 
eliminating many tumor cells, others acquire additional mutations as a result of immune 
pressure (so-called immune editing) and become less immunogenic, leading to an 
equilibrium between the tumor and immune cells. This stage of cancer is often not 
detected clinically and can last for decades 8. Once equilibrium is reached, select tumor 
cells are able to escape the immune system by becoming less ‘visible’ to the immune 
system through downregulation of MHC or antigen expression, or by recruiting 
immunosuppressive cells to the microenvironment, such as regulatory T cells. 
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Therefore, tactics to educate and stimulate the immune system against tumor cells has 
gained interest.  
1.2 IMMUNOTHERAPY  
1.2.1 Coley’s Toxins 
Coley’s toxins were first used in the late 1800s, when William Coley injected 
Streptococcal pyogenes into a patient with an inoperable tumor in hopes of awakening 
the “resisting mechanisms” or immune system 9. He had previously observed tumor 
regression after a patient had come down with a skin infection and high fever, which 
inspired him to try this approach. His first patient responded to therapy and led to more 
than 40 years of Coley treating patients with Streptococcal pyogenes or Serratia 
marcescens. He later became known as one of the “Fathers of Immunotherapy”; 
however, his immunotherapeutic approach was halted due to unreliable success rates 
in the 1960s by the FDA with the rise of radiation and chemotherapy. 
1.2.2 Vaccines 
Therapeutic vaccines were first utilized in the late 1800s by combining a patient’s 
irradiated tumor cells with an adjuvant to stimulate the immune system 10. A GM-CSF 
transduced tumor vaccine (GVAX) was later developed; however, while it showed 
limited efficacy in the clinic as a monotherapy, it has since been combined with 
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checkpoint inhibitors for the treatment of patients with prostate cancer as well as listeria-
expressing mesothelin for pancreatic cancer 11, 12, 13, 14. Therapeutic vaccinations have 
been developed in other cancers such as melanoma by loading DCs with tumor 
peptides and in breast cancer through development of a vaccine against the HER2 
antigen 15, 16.  
1.2.3 Adoptive Cell Therapy 
Adoptive cell therapy (ACT) is the isolation, expansion, and re-administration of a 
patient’s own immune effector cells to target their cancer 17. The most successful 
application of this is the development of chimeric antigen receptor (CAR) T cell therapy. 
CAR T was initially used in relapsed pediatric liquid tumors (ALL) with response 
occurring in most of the patients 18, 19. Since this time, CAR T has been FDA approved 
for pediatric ALL and has recently been used in adult ALL as well. 
1.2.4 Antibodies 
Immunotherapy developed a renewed focus of cancer therapy 7 years ago, when an 
antibody targeting the inhibitory receptor, CTLA-4 (Ipilimumab), showed a ~20% 
increase in overall survival in metastatic melanoma patients and was FDA approved. 
Interest in immunotherapy grew rapidly a few years later when another antibody 
targeting PD-1 (Nivolumab) was approved with better than anticipated patient 
responses, showing a 40% objective response rate in melanoma patients 20, 21, 22, 23, 24. 
The underlying mechanisms of resistance to immunotherapy are not fully understood. 
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One potential roadblock is the presence of suppressive cell populations, primarily 
Tregs25.  
1.3 REGULATORY T CELLS 
1.3.1 Treg Characteristics and Function 
Tregs function as the master regulators of the immune system, providing the much 
needed ‘breaks’ to reign in the immune response in order to maintain homeostasis and 
prevent autoimmunity. Initially identified as ‘suppressor cells’ 26, these cells were later 
characterized by expression of the transcription factor Foxp3 in mice 27. These cells can 
develop in the thymus (tTregs), arise in the periphery (pTregs), or be generated in vitro 
with the addition of TGFβ (iTregs) 28. I will primarily focus on tTregs (herein denoted as 
‘Tregs’); however, the role of pTregs in tumors, their stabilizing factors, and whether they 
become fragile in tumors remains unclear and warrants further investigation.  
Treg function is exerted through a variety of mechanisms such as (1) cytokine 
secretion (including IL-10 and IL-35), (2) metabolic disruption through CD39:CD73 
adenosine production pathways or IL-2 deprivation, (3) direct cytolysis through 
Granzyme B delivery through perforin pores, and (4) dendritic cell targeting through 
upregulation of LAG3 and CTLA4 29. In the absence of Tregs or when the Foxp3 locus is 
disrupted, rampant autoimmunity ensues. This presents as IPEX (immune disregulation 
polyendocrinopathy, enteropathy, x-linked) in patients and is lethal without allogenic 
bone marrow transplantation 30, 31. A similar disease occurs in mice bearing the Scurfy 
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mutation 32, 33 but can be prevented through Treg cell transfer within 48 hours of birth 34. 
While Tregs are critical for preventing autoimmunity, they also suppress the anti-tumor 
immune response and promote tumor outgrowth 35. Indeed, a higher CD8:Treg ratio is 
predictive of response to combination radiation and anti-CTLA4 in mice 36. Furthermore, 
many cancer types show a positive correlation between higher Treg percentages and 
poor prognosis in patients 37, 38.  
1.3.2 Targeting Tregs 
Tregs have been targeted therapeutically, primarily through depletion strategies, in both 
mice and in the clinic with limited success. Treg depletion in tumor models has been 
studied in Foxp3DTR-GFP mice, where, while the majority of mice clear the tumor, they 
ultimately succumb to systemic autoimmunity 39. In the clinic, Treg depletion has been 
the primary strategy, resulting in limited response or off target effects. Depletion 
strategies targeting the IL-2 pathway through use of antibodies like anti-CD25 or other 
small molecules led to off-target effects such as depletion of effector T cells or loss of 
DC-mediated T cell activation 40, 41. Striking a balance between sustained Treg depletion 
and autoimmunity prevention has proven difficult, further highlighting the need to target 
Treg function specifically within the TME rather than eliminating the cell population 
systemically. 
Intratumoral Tregs bear a distinct transcriptional and functional profile in 
comparison to those found in the periphery, including upregulation of activation and 
suppressive molecules, such as CD44, CD39, and ICOS 42. Other markers promoting 
Treg function are significantly increased in the tumor microenvironment in both mouse 
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models and patient samples, such as the surface receptor, Neuropilin-1 (Nrp1) 43. While 
Nrp1 can be expressed on a number of cell types, it is highly upregulated on Tregs and 
supports Treg function through binding of Semaphorin-4a (Sema4a). Upon Sema4a:Nrp1 
ligation, PTEN is recruited to the immunological synapse and limits Akt activity, thus 
increasing translocation of FOXO1/3a to the nucleus 43. In the absence of Nrp1 
signaling, either through Nrp1 blockade or genetic deletion (using Nrp1L/LFoxp3Cre-YFP 
mice), intratumoral Tregs show reduced cell survival and expression of suppressive 
markers such as CD73 and IL-10, and significantly impaired suppressive function, while 
maintaining Foxp3 expression. As a result, Nrp1L/LFoxp3Cre-YFP mice cleared tumors 
similarly to mice lacking Tregs; however, the mice displayed no signs of autoimmunity. 
Nrp1+ Tregs are also increased in metastatic melanoma and head and neck squamous 
cell carcinoma patients compared to healthy donors. Furthermore, patients with a larger 
population of Nrp1+ Tregs correlated with reduced disease-free survival in comparison to 
those with a smaller population 44. The distinction between peripheral and intratumoral 
Tregs suggests that there are specific markers one could target within the TME leading to 
Treg instability (dysfunction and loss of Foxp3 expression) or Treg fragility (dysfunction 
while maintaining Foxp3 expression).  
1.3.3 Challenges 
A critical concern in targeting or utilizing Tregs therapeutically is their stability, as defined 
by the maintenance of Foxp3 expression and suppressive activity, while not exhibiting 
pro-inflammatory effector function. While continued Foxp3 expression has been the 
primary determinant of Treg stability, it has become apparent that this alone does not 
 8 
define ‘stability’.  Indeed, there are many additional factors and mechanisms that need 
to be considered, including epigenetic modifications and expression of activating or 
regulatory factors, as examples of Treg instability and loss of function have been 
described despite continued Foxp3 expression 45, 46. I will primarily focus on thymically-
derived Tregs (tTregs) 28.  The stability of induced Treg populations, such as peripherally 
derived Tregs (pTregs), has been discussed elsewhere 45, 47, 48 
1.4 NEUROPILIN-1 
Neuropilin-1 (Nrp1) is a type 1 transmembrane receptor that is composed of a large 
extracellular domain, a single transmembrane domain, and a short intracellular domain. 
Nrp1 can bind to Semaphorins and VEGF through the extracellular domain and results 
in enhanced axonal guidance and angiogenesis respectively 49, 50, 51.  
Nrp1 is expressed on many immune cell types, including DCs and T cells 52, 53. 
More recently, our lab has highlighted a role for Nrp1 in immune cells, specifically that it 
contributes to Treg stability upon binding of Sema4a 43. While Nrp1 can be expressed on 
other immune populations, such as CD8+ T cells, it is highly upregulated on Tregs and is 
thought to be a distinguishing marker of thymically derived Tregs from peripheral Tregs in 
mice 54, 55. Nrp1 is upregulated on intratumoral Tregs and contribute to their suppressive 
function through binding to Sema4a binding, which can be expressed by T cells, NK 
cells, and DCs 43.  Upon binding to Sema4a, Nrp1 recruits PTEN to the immunological 
synapse, thereby restraining Akt activity, leading to Foxo1/3a translocation to the 
nucleus and subsequent stabilization of Foxp3. Nrp1 is also expressed on human Tregs 
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in patient PBL and tumor samples, but is expressed at very low levels in healthy donor 
PBL in contrast to mice. It is thought to contribute to their suppressive function in the 
TME as patients with higher percentages of Nrp1+ Tregs have a poorer disease-free 
survival in both HNSCC and metastatic melanoma 44. 
1.5 INTERFERON-γ 
Interferon-γ (IFNγ) is a type II interferon composed of homodimerized glycosylated 
monomers that is secreted primarily by T cells, NK cells, and NKT cells that activates 
macrophages, endothelia, and surrounding T cells. IFNγ can be induced through IFNγ 
in a feed-forward loop or through IL12 and IL18 uptake 56, 57. IFNγ binds IFNγR1/2 and 
signals through Jak1/2 to phosphorylate Stat1. This in turn homodimerizes, translocates 
to the nucleus, and binds gamma-interferon activated sites (GAS) 58.  IFNγ was first 
appreciated in tumor immunology when a methylcholanthrene (Meth A) tumor cell line 
grew more rapidly in vivo following treatment with an IFNγ antibody 6, 59. Other studies 
have shown that IFNγ can act directly on tumor cells through the use of Ifngr1–/– cell 
lines that grew more rapidly in vivo in comparison to WT lines. Interestingly, mice with 
Ifngr1–/– tumors are resistant to anti-CTLA4. In addition, patients with tumors that lack 
IFNγ signaling are also less responsive to CTLA4 therapy, suggesting that this may be 
a mechanism of resistance to immunotherapy 60.  
While it has been previously shown that Tregs can produce IFNγ in the presence of IL12 
and are less suppressive in vitro, the role of IFNγ+ Tregs in the tumor microenvironment 
remained unclear. I have now shown that IFNγ can also lead to loss of Treg function that 
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may be required for response to checkpoint blockade 44. Indeed, loss of the IFNγR on 
Tregs led to complete resistance to PD-1 blockade in mice. In addition, treating either 
mouse or human Tregs with IFNγ led to reduced suppression, suggesting that it is 
sufficient to drive Treg loss of function. 
1.6 WHAT DOES TREG STABILITY MEAN AND HOW IS IT ASSESSED?  
Fundamentally, I would argue that Treg stability should be defined by the maintenance of 
all of the following characteristics: (1) sustained Foxp3 expression, (2) potent 
suppressive activity, and (3) lack of effector activity (eg. production of IL2 and pro-
inflammatory cytokines, cytolysis, B cell help, etc).  While there are observations that 
challenge this definition, such as the expression of lineage defining transcriptions 
factors T-box 21 (Tbet) 61, Interferon regulatory factor 4 (IRF4) 62 and Signal transducer 
and activator of transcription 3 (STAT3) 63 by Tregs, these fundamental characteristics 
are nonetheless maintained.   
Stable Foxp3 expression is thought to be maintained by specific epigenetic 
modifications. For instance, a Conserved Noncoding Sequence 2 (CNS2, also known as 
Treg Specific Demethylated Region, TSDR) in the 5’ UTR of Foxp3, comprised of a 
series of CpG motifs is hypomethylated in Tregs but hypermethylated in naive or effector 
T cells 45, 64. This hypomethylated pattern is maintained in an IL-2 dependent manner 45. 
A fully methylated locus is considered to be closed and thus not transcriptionally active, 
while an unmethylated locus is open and active 65. Indeed, the increased CNS2 
methylation seen in TGFβ-induced Tregs is thought to underlie their instability 48. A 
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genome wide analysis has suggested that hypomethylation at other loci such as Il2ra 
(CD25), Ikzf4 (Eos), Ctla4 (Cytotoxic T-lymphocyte-associated protein 4) and Tnfrsf18 
(GITR), may also be important for Treg stability 48. Although all of these loci show a 
similar hypomethylation pattern to Foxp3 in Tregs, Foxp3 CNS2 demethylation is reliant 
on DNA methyltransferases, such as DNMT1 66, while the other loci are not. 
Furthermore, it was recently shown that Tet methylcytosine dioxygenase 2 (Tet2) is 
required for Foxp3 CNS2 hypomethylation 67, 68. In fact, overexpression of Tet2 leads to 
hypomethylation and stability of Foxp3 regardless of IL-2 expression. These reports 
suggest a role for epigenetic alterations in maintaining Foxp3 expression and Treg 
stability. 
Treg stability has been a controversial topic for a number of years 69. Many studies 
have suggested that Treg development leads to a terminally differentiated population, 
albeit with a number of different suppressive functions determined by the surrounding 
milieu 70. Indeed, some have suggested that Tregs are one of the more stable cell 
lineages, based on lineage tracing experiments with Foxp3CreERT2-GFPRosaLSL.YFP mice. 
These mice allow for tamoxifen-inducible expression of Foxp3-driven Cre in Tregs, which 
permanently marks these cells with YFP regardless of subsequent Foxp3 expression 64. 
Using this approach, very few if any Tregs appear to lose Foxp3 expression and become 
“exTregs” up to 5 months after tamoxifen injection. In addition, the majority of Tregs 
maintained Foxp3 expression even under IL-2 deprivation, and although some cells had 
a minor decrease in Foxp3 expression, they maintained their suppressive activity and 
exhibited a normal pattern of cytokine secretion.  Treg stability has also been tested in a 
limited number of disease scenarios, such as Listeria monocytogenes and diabetes. 
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When given a sub-lethal dose of Listeria monocytogenes, TH1 transcription factors such 
as Tbet and Cxcr3 were increased in both Foxp3+ and Foxp3– T cells, but Foxp3 
expression was largely maintained 64.  To assess Treg stability in an autoimmune setting, 
pure GFP+ cells from BDC2.5 TCR-transgenic Foxp3GFP NOD mice were transferred to 
lymphoreplete NOD Thy1.1 mice.  Transferred Tregs infiltrated islets by 4 weeks after 
injection, and were almost exclusively Foxp3+.  
However, other studies have suggested that Tregs can lose Foxp3 expression and 
take on a pro-inflammatory, memory-like phenotype in certain disease environments 71. 
Using a Foxp3Cre-GFPRosaLSL.YFP BAC transgenic mouse in which Cre is expressed by all 
Tregs and YFP marks all cells that have Foxp3, it was noted that a small percentage of 
mature Tregs had lost Foxp3 expression (10-20%) 72, 73. These exTregs had increased 
Foxp3 CNS2 methylation compared with stable Treg counterparts, suggesting instability. 
These cells displayed an activated-memory phenotype as noted by increased CD44 
expression and IFNγ secretion. When Foxp3Cre-GFPRosa LSL.YFP NOD mice were 
analyzed to assess the role of exTregs in a disease setting, a moderate percentage of 
exTregs was observed in the islets (30-35%) 72. These cells were also capable of 
inducing autoimmune diabetes, as shown following adoptive transfer of BDC2.5 TCR 
transgenic Tregs. Interestingly, when purified and cultured in vitro, up to 20% of the Tregs 
lost Foxp3 expression. 
The topic of Foxp3 stability remains controversial.  However, there are a number 
of potential reasons why different conclusions may have been reported. First, the 
mouse strains used to assess Treg stability are designed differently. Whereas a Foxp3Cre 
BAC transgenic mouse labels all cells that express Foxp3 early in development, 
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Foxp3CreERT2 mice label Foxp3+ cells only upon tamoxifen injection. In addition, BAC 
transgenic mice sometimes don’t exhibit entirely faithful promoter expression that is 
identical to the endogenous promoter due to the location of insertion and the influence 
of local control elements. Second, different methods were used to isolate Tregs, such as 
double versus single sorting, before transfer into a new host. It is possible that the 
observed exTregs could have been generated by cellular stress or derived from 
contamination, either from Foxp3— cells or cells that transiently upregulated Foxp3 
during development.  Third, it is also possible that T cells transiently upregulate Foxp3 
during development leading to ‘false labeling’ of cells that are not destined to become 
bona fide Tregs, as indicated by hypermethylation at the Foxp3 CNS2. Some Foxp3+ T 
cells also transiently lose Foxp3 expression, which leads to a partially methylated 
CNS2. However, upon reactivation, these cells reacquire a hypomethylated CNS2, 
indicating lineage commitment 74. Indeed, it was previously shown that a small subset of 
naïve cells transiently co-expresses RORγt and Foxp3, producing either TH17 or Treg 
cells depending on the surrounding environment 75. Transient Foxp3 expression has 
also been observed in human T cells, although these cells have no suppressive function 
76.  While a few reports suggest that a small percentage of exTregs exist, two points 
remain: (1) Are they simply undergoing transient expression of Foxp3?  (2) If they are a 
separate subset, do they impact specific diseases? Regardless of whether one 
considers Tregs stable or occasionally unstable, an overriding question is how is Treg 
stability maintained? 
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1.7 HOW IS TREG STABILITY MAINTAINED? 
While Foxp3 is required for maintaining Treg stability, there are several reports 
suggesting that Treg stability is supported and enforced by other factors, such as IL-2, 
Foxo1/3a, Eos, a member of the Ikaros family of transcription factors, and Nrp1.  
Once Foxp3 is upregulated, expression must be maintained to preserve Treg 
function and stability. Many factors are involved in this, including the IL-2/STAT5 
pathway. In fact, Foxp3 expression is significantly diminished in Il2rb–/– (CD25) mice, 
while STAT5 deletion prevents Treg development. Indeed, STAT5 binds to the Foxp3 
promotor region, leading to stabilization of the locus 77. Foxp3 is also modulated by 
other members of the Forkhead box family, Foxo1 and Foxo3a 78. Foxo1/3a prevent 
Tregs from taking on effector functions 79, 80. In the absence of Foxo1, Treg development is 
diminished, and those that do develop are unable to suppress in vitro. Indeed, in the 
absence of Foxo1, T cells express more IFNγ, leading to severe autoimmunity in vivo 81. 
This is further exacerbated in the absence of both Foxo1 and Foxo3a 82. Stable Tregs 
show reduced Akt expression, leading to enhanced Foxo1 and Foxo3a in the nucleus, 
where they stabilize Foxp3 expression by binding to the promotor region and regulating 
other transcription factors 83.  
Eos, a zinc-finger transcription factor, was identified as a critical facilitator of Treg 
stability 84. Indeed, Eos-limited Tregs exhibited enhanced expression of IL-2 and IFNγ 
along with reduced suppressive capacity, but showed no difference in the expression of 
Foxp3. Forced overexpression of Eos prevented Treg reprogramming, even in 
destabilizing environments, maintaining CTLA-4 expression and preventing CD40L, IL-2 
and IL-17 expression.  Eos–Foxp3+ Tregs (Eos-labile) were later identified in vivo and 
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were also shown to have reduced regulatory function 85. Eos-labile Tregs were capable of 
functional reprogramming, shown through adoptive transfers into Cd40lg–/– mice, which 
lack efficient priming of naïve CD8 cells.  Indeed, when transferred into CD40L-deficient 
hosts, a subset of Tregs downregulated Eos and upregulated CD40L to provide help for 
CD8 priming. Therefore, both Eos-labile and Eos-stable Tregs suppress and maintain 
Foxp3 expression, but the former maintains the ability to reprogram and display helper 
activity in certain environments. However, whether Eos-labile and Eos-stable Tregs are 
two distinct subsets, or if Eos expression enhances stability, is unknown. 
A pathway that is important for maintaining Treg stability in a manner that appears 
to be independent of Foxp3 expression is the Neuropilin-1:Semaphorin-4a axis 43. The 
majority of mouse Tregs express high levels of Nrp1 86 and this contributes to their 
function and stability 43, 87.  Nrp1 has also been shown to increased angiogenesis and 
CD8 activation in a VEGF-dependent manner 43, 87. When Nrp1 was blocked in vitro, 
Tregs were capable of suppressing in classic contact-dependent suppression assays, but 
were incapable of suppressing across a permeable transwell, where suppression is 
mediated by IL-10 and IL-35 88 . Nrp1L/LFoxp3Cre mice showed no signs of autoimmunity 
and remained healthy well past one year of age, indicating that Nrp1-deficient Tregs were 
capable of maintaining immune homeostasis. However, when injected with 
transplantable tumors (B16, EL4, MC38), tumor growth was substantially reduced. 
While tumor clearance was also observed in most cases, no autoimmunity or 
inflammatory lesions were observed. Therefore, Nrp1-deficient Tregs lost stability and 
suppressive capacity in the tumor microenvironment, while maintaining stability in the 
periphery, likely due to destabilizing factors that were confined to the tumor 
 16 
microenvironment. Blocking antibodies to Nrp1 or Sema4a were also found to limit 
tumor growth. Nrp1-deficient Tregs maintained Foxp3 expression, but showed alterations 
in other critical Tregs markers, such as a decrease in ICOS, IL-10 and CD73. Further 
mechanistic analysis showed that Nrp1:Sema4a ligation leads to the recruitment of 
PTEN, which limits Akt activity, leading to increased nuclear translocation of Foxo1 and 
Foxo3a, thereby stabilizing Foxp3 expression. This leads to an enhancement of 
quiescence and survival factors (Klf2, Bcl2) and effector molecules (IL-10, CD73), while 
limiting lineage-defining transcription factors (T-bet, IRF4, Rorγt) and effector molecules 
(IFN-γ).  These data suggest that Treg stability can occur independently of Foxp3 
expression.  
In summary, I would argue that Treg stability can be defined by the maintenance 
of three critical traits: (a) stable Foxp3 expression, (b) efficient suppressive activity, and 
(c) a lack of effector activity.  Several factors appear to contribute to and are required for 
the maintenance of this stable phenotype, including demethylation of the Foxp3 CNS2 
locus, the transcription factors Foxo1/3a and Eos, and the Nrp1:Sema4a axis.  
However, many questions remain. (1) Are there other factors or mechanisms that 
are required for the maintenance of Treg stability?  (2)  What is the functional relevance 
of Foxp3 CNS2 hypomethylation, given that this is not always required for Foxp3 
expression? (3) Is Treg stability engrained during development or does it have to be 
continually and actively reinforced in the periphery?  (4) Do exTregs or destabilized 
Foxp3+ Tregs have distinct and unique functions, and if so, how can one track or target 
these cells in humans?  (5) How can one utilize or target Treg stability in disease? 
 17 
Limiting or enhancing Treg stability provides a novel therapeutic strategy for a 
wide variety of diseases. For example, inducing Treg instability in tumors could lead to an 
improved response to immunotherapies, while enhancing Treg stability could limit 
transplant rejection, autoimmunity, and inflammatory disease.  Clearly, more research is 
required to further understand how Treg stability is maintained and its functional 
relevance in various disease settings.  
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2.0  METHODS 
2.1 EXPERIMENTAL MODEL AND SUBJECT DETAILS 
2.1.1 Mice 
Nrp1L/L mice were obtained from D. Cheresh (UC San Diego). Foxp3Cre-YFP/Cre-YFP, 
Foxp3DTR-GFP/DTR-GFP, Foxp3–/– mice were obtained from A.Y. Rudensky (Memorial Sloan 
Kettering). 27, 39, 89. Ifngr1–/–, Ifng–/–, Ifngr1L/L, Hif1aL/L and RosaL-Tomato-L-GFP mice were 
obtained from Jackson Laboratories 90, 91, 92. All animal experiments were performed in 
the American Association for the Accreditation of Laboratory Animal Care-accredited, 
specific-pathogen-free facilities in Animal Resource Center, St. Jude Children’s 
Research Hospital (SJCRH), and Division of Laboratory Animal Resources, University 
of Pittsburgh School of Medicine (UPSOM). Female and male mice were used. Animal 
protocols were approved by the Institutional Animal Care and Use Committees of 
SJCRH and UP. 
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2.1.2 Human T-cell populations 
All HNSCC and melanoma tissues were acquired under a University of 
Pittsburgh Cancer Institute Institutional Review Board (IRB)-approved protocol with 
written informed consent obtained from each patient in conjunction with the University of 
Pittsburgh Cancer Institute HNSCC and Melanoma SPOREs. There were no restrictions 
on cancer subtype, smoking status, age, race, or prior adjuvant therapy. Control donor 
peripheral blood (PBL) was collected through an approved MTA protocol with the 
Western Pennsylvania Bloodbank. Human HNSCC PBL and TIL samples (unmatched) 
as well as healthy donor PBL samples were provided by R. Ferris from patients with 
high-risk, advanced (stage III or IV) resectable HNSCC treated with surgery. Most 
tumors were from oral cavity or laryngeal sites, and all were HPV-negative. Tumor 
specimens were obtained at the time of surgical resection, prior to adjuvant therapy. TIL 
were isolated, frozen, and thawed prior to staining for NRP1. Freshly processed 
samples were used in functional assays. Human melanoma TIL and PBL samples were 
provided by J. Kirkwood from an accrual trail (96-099) of patients with metastatic 
melanoma.   
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2.2 METHOD DETAILS 
2.2.1 Antibodies and flow cytometry 
Single cell suspensions were stained with antibodies against CD4 (clone# GK1.5, 
Biolegend), CD8α (clone# YTS156.7.7, Biolegend; clone# H35-17.2, eBioscience), 
TCRβ (clone# H57-597, Biolegend), Thy1.1 (clone# OX-7, Biolegend), Thy1.2 (clone# 
30-H12, Biolegend), Foxp3 (clone# FJK-16s, eBioscience; clone# 150D, Biolegend),  
IFNγ (clone# XMG1.2, Biolegend), ICOS (clone# C398.4A, Biolegend), phospho-Stat1 
(Clone# 4a, BD Biosciences) and phospho-Stat4 (Clone# 38, BD Biosciences). Surface 
staining was performed on ice for 15min. For cytokine expression analysis, cells were 
activated with 0.1ng/ml PMA (Sigma) and 0.5ng/ml Ionomycin (Sigma) in RPMI 
containing 10% FBS and Monensin (eBioscience) for 8hr. For intracellular staining of 
cytokines and transcription factors, cells were stained with surface markers, fixed in 
Fix/Perm buffer (eBioscience) for 15 minutes, washed in permeabilization buffer 
(eBioscience) twice and stained intracellular factors in permeabilization buffer for 30min 
on ice. For phosphoprotein staining, cells were fixed with 1.5% PFA (Alfa Aesar) at 
37°C for 15min, permeabilized with ice cold Methanol for 1hr, and stained on ice for 1hr. 
Cells were sorted on Aria II (BD Biosciences) or analyzed on Fortessa (BD 
Biosciences), and data analysis was performed on FlowJo (Tree Star). 
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2.2.2 Fusion Proteins 
The sequence encoding the extracellular domains of Sema4a and Nrp1were 
cloned in-frame to pX-Ig to create a Sema4a- or Nrp1-mouse IgG1 fusion protein 
construct (Sema4a-IgG1 and Nrp1-IgG1). J558L B cells were electroporated with this 
construct, and high-producing clones were selected by single-cell sorting. High-
producing clones were seeded into Sartorious Bioreactors and collected for protein G 
purification and concentration. Sulphate latex 4-µm beads (Life Technologies) were 
conjugated with isotype control (mouse IgG1, MOPC21, R&D Systems) or Sema4a-Ig 
overnight with 3 pg protein per bead, blocked with 10% FBS, and stored in media. 
Mouse Sema-3a-Fc, Sema4a-Fc, mouse Nrp1, and human Sema4a-Fc was purchased 
from R&D Systems. 
2.2.3 Tumor models 
Mice were injected with either B16.F10 melanoma (1.25 × 105 cells or 50,000 
cells intradermally), MC38 adenocarcinoma (5x105 cells subcutaneously). Tumors were 
measured every 3 days with digital calipers and tumor size was calculated; this was 
performed in blinded manner but not randomized. 100ug Diptheria Toxin was injected 
every 3 days starting on day 7 in Foxp3DTR-GFP/DTR-GFP and Foxp3DTR-GFP/+ mice. 
Sema4aIg was injected every 3 days starting on day 5 (400ug, 200ug, 200ug), and anti-
CD8 (YTS) was injected every 3 days starting on day 5 (200ug). Foxp3Cre-YFP and 
Ifngr1L/LFoxp3Cre-YFP mice were treated with either anti-PD1 (clone G4) or isotype 
(Armenian Hamster IgG), “AIPV”, anti-LAG3, or anti-GITR. Tumors and non-tumor 
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draining lymph nodes were collected for analysis on day 12. TILs were prepared with 
enzymatic (collagenase IV and dispase, 1mg/mL) and mechanical disruption. In 
Appendix A, therapeutic B16 experiments were conducted by injecting 1.25 × 105 B16 
melanoma cells intradermally and waiting until tumors were palpable (5 days). On 
day 5, mice began to receive intraperitoneal injections of either rat IgG2a, or anti-
Nrp1 (R&D Systems clone 761704, MAB59941) (400 µg initial dose and 200 µg every 
3 days). Prophylactic experiments included anti-Sema4a (R&D Systems clone 
757129) and Sema4a-IgG1 consisting of twice weekly injections of 100 µg of protein 
starting on the day of tumor inoculation. To achieve reasonable power, at least 3 mice 
were used per group per experiment. Group means were compared with Student’s t 
tests. Tumor growth over time was analyzed using two-way ANOVA with multiple 
comparisons. Event-free survival (moribund) estimates were calculated with the Kaplan-
Meier method. Groups of mice were compared by log-rank test. All p values are two-
sided, and statistical significance was assessed at the 0.05 level. Analyses were 
conducted using GraphPad Prism software. 
2.2.4 Foxp3–/– model  
CD45.1+ Foxp3+/– female mice were bred with CD45.1+Foxp3+/+ male mice in 
timed matings. Male progeny were genotyped at birth for Foxp3–/– status. Tregs from 
Thy1.1+ Foxp3Cre-YFP/Cre-YFP, Thy1.2+ Nrp1L/LFoxp3Cre-YFP/Cre-YFP, Thy1.2+ Ifng–/–
Nrp1L/LFoxp3Cre-YFP/Cre-YFP, Thy1.1+ Ifngr1–/–Foxp3Cre-YFP/Cre-YFP mice were purified by 
FACS and 106 cells injected intraperitoneally into Foxp3–/– male pups within 2 days of 
birth 34. When a 50:50 mixture of Tregs was injected the total was maintained at 106 cells.  
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Mice were monitored for the autoimmune phenotype ‘scurfy’ (scaly skin, eye 
inflammation, runted phenotype, and lack of mobility) 34. Any mice exhibiting any 
autoimmune or inflammatory symptoms prior to B16 injection, even if mild, were 
removed from further study.  Mice were injected with 1.25x105 B16.F10 cells at 4 weeks 
of age and tumor growth was monitored every 3 days. 
2.2.5 Gene expression profiling by RNAseq and bioinformatics analyses 
Tregs (5x103) were either single (n=3) or double sorted (n=2) and cDNAs were 
prepared using the SMARTer® UltraTM Low Input RNA Kit for Sequencing - v3 user 
manual (Clontech Laboratories). I reasoned that double sorting results in higher purity 
but has lower yield and may alter the expression profile. Though melanoma genes were 
found at lower levels in double sorted samples no other substantial differences, such as 
activation of stress response genes, were observed. Tregs were sorted on the following 
markers: Foxp3Cre-YFP/Cre-YFP (Nrp1+/+) on YFP, Nrp1L/LFoxp3Cre-YFP/Cre-YFP (Nrp1–/–) on 
YFP, Nrp1L/LFoxp3Cre-YFP/DTR-GFP (Nrp1–/–) on YFP, and Nrp1L/LFoxp3Cre-YFP/DTR-GFP 
(Nrp1+/+) on GFP. Sequencing libraries were prepared using Nextera XT DNA Library 
Preparation kit (Illumina), normalized at 2nM using Tris-HCl (10mM, pH 8.5) with 0.1% 
Tween20, diluted and denatured to a final concentration of 1.8nM using the Illumina 
Denaturing and Diluting libraries for the NextSeq 500 protocol Revision D (Illumina). 
Cluster generation and 75bp paired-end dual-indexed sequencing was performed on 
Illumina NextSeq 500 system.  
RNAseq data was aligned to the mm10 genome using the STAR aligner 93 and 
quantified using featureCounts 94. The raw counts data were processed using the 
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“voom” function  95 in the limma R package 96, 97, which normalizes the data and assigns 
a weight for each measurement for subsequent linear model fitting. Unsupervised 
analysis of the data revealed a small cluster of melanoma specific genes that I 
reasoned were caused by contaminations. Following a previous approach 98, Dr. Maria 
Chikina removed five melanoma specific genes from all downstream analysis (Mlana, 
Syt4, Tyr, Tyrp1, Dct ). To filter for low expression genes. Dr. Chikina defined a cutoff of 
90 reads per gene based on visual inspection of the bimodal count distribution. Only 
genes that met this threshold in at least 5 samples (~11,000 out of ~23,000) were kept 
for further analysis. Differential expression was assessed using the limma moderated T 
statistic. The differences between the intratumoral Treg populations were subtle and in 
order to increase the power of my study Dr. Chikina included technical factors as 
covariates in my differential expression analysis. Following the approach outlined in a 
recent human RNAseq study 98. Dr. Chikina included three Picard 99("picard,") RNAseq 
metrics ("PCT_INTERGENIC_BASES" "MEDIAN_3PRIME_BIAS", 
"MEDIAN_CV_COVERAGE" ) 99 as well GC correlation (computed as the sample 
specific Pearson correlation between each gene's GC content and its expression value). 
Normalization for replicate number and technical parameters was also applied directly 
to the voom result to obtain "normalized counts", which were used for data visualization. 
Geneset enrichment was performed using the “RankSumWithCorrelation” function in the 
limma R package, which automatically corrects enrichment statistic inflation due to 
correlation among genes (with the immune genesets restricted to those relevant to T 
cells).  p-values were combined from the “Nrp1L/LFoxp3Cre-YFP/Cre-YFP (Nrp1–/–) vs 
Foxp3Cre-YFP/Cre-YFP (Nrp1+/+)” and “Nrp1L/LFoxp3Cre-YFP/DTR-GFP (Nrp1+/+) vs 
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Nrp1L/LFoxp3Cre-YFP/DTR-GFP (Nrp1–/–) using the Fisher’s “log sum” method [Fisher] to 
define significant genes. Genesets with a q-value FDR of <0.2 were considered 
significant. In order to assess the alterations in Treg specific expression profile I relied 
on the Treg signature genes defined in a previous study 100. For pathway analysis bar 
charts, results of geneset enrichment analysis were depicted with colors representing 
the effect size and height representing the corresponding p-values. The effect size is 
defined as AUC (area under receiver operating curve) – 0.5 which provides a 
normalized ranksum statistic that is comparable across genesets of different sizes. The 
plot is restricted to the top 10 pathways (based on their Nrp1+/+ vs Nrp1–/– significance) 
from the “canonical” mSigDB geneset. Dr. Maria Chikina additionally restricted this 
analysis to genesets and pathways that were deemed relevant to intercellular signaling 
(defined at least half of the genes in the geneset having an extracellular or membrane 
annotation). 
2.2.6 In vitro assays  
Splenic CD4+YFP− (CD4+Foxp3– T cells) cells from Foxp3Cre-YFP mice were sorted 
as responder cells and labeled with 5μM CellTrace Violet (Life Technology). CD4–CD8– 
splenocytes from Foxp3Cre-YFP mice were treated with 20μg/mL mitomycin C (Sigma) at 
37°C for 30min, washed five times with PBS, and then used as antigen presenting cells 
(APCs). Responder cells (4x103), APCs (8x103), and different concentrations of Tregs 
(1:2-1:16 Treg:Teff ratio, 500-2000 Tregs) were activated with 2µg/ml anti-CD3 (Biolegend) 
in a 96-well round bottom plate with 100ul RPMI for 3 days 101. Suppression was 
calculated as previously described 102. Briefly, cells were acquired by BD Fortessa, and 
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the division index of responder cells was analyzed using FlowJo based on the division 
of CellTrace Violet. Suppression was then calculated with the formula % Suppression = 
(1-DITreg/DICtrl) x 100% (DITreg stands for the division index of responder cells with 
Tregs, and DICtrl stands for the division index of responder cells activated without Tregs). 
Human microsuppression assays were performed similarly to mouse assays with the 
following changes: 0.5µg/ml anti-CD3 is used for activation, and cells are cultured in 
assay conditions (200uL) for 4 days. 
For co-culture assays, sorted Treg populations were cultured together in a 96 well 
round-bottom plate or in a 96 well transwell plate (Millipore) for 72 hours prior to being 
resorted and used in a suppression assay. Cells were treated with 100ng/mL PMA 
(Sigma), 500ng/mL Ionomycin (Sigma) and 1000IU hIL-2 (Prometheus) for co-culture. 
For some experiments, sorted Tregs were cultured in the presence of 0.3-20ng/mL anti-
IFNγ (BioXcell) or 0-200ng/mL IFNγ (Biolegend) to the microsuppression assay. 
For the hypoxia assays, Tregs were stimulated with PMA/Ionomycin and IL-2 for 3 
days in normoxic (5% CO2 and 20% O2) or hypoxic (5.5% CO2 and 1.5% O2) conditions 
at 37˚C. Cells were then stained in the same condition in the absence of cytokine. 
2.2.7 Microscopy 
Foxo3a was carried out on freshly isolated Treg cells that were left unstimulated in 
media overnight or stimulated with immobilized anti-CD3 and anti-CD28 in the 
presence or absence of immobilized Sema4a-IgG1 or its isotype control. Cells were 
collected, fixed in 1% PFA, and permeabilized with 0.1% Triton X-100 in TBS. After 
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blocking with normal mouse serum, cells were stained with anti-Foxo3a (Cell 
Signaling Technologies) overnight in Tris-buffered 1% BSA. After several washes, 
cells were stained with Alexa Fluor 647 conjugated anti-rabbit IgG (Life 
Technologies), and then washed several times. Cells were then loaded with 4′,6-
diamidino-2-phenylindole (DAPI) and phalloidin-Alexa Fluor 546 or 488 before 
microscopy. Random fields of 10 to 30 cells were visualized using spinning-disc 
laser-scanning confocal microscopy. Blinded masks were generated using phalloidin 
and DAPI staining to determine cytoplasmic and nuclear volume, respectively, and 
only then was the Foxo3a staining visualized. The nuclear and cytoplasmic volumes 
of Foxo3a fluorescence of 20 to 30 stacks were calculated using Slidebook (3i) 
software in arbitrary fluorescence units and analyzed in Graphpad Prism. 
2.2.8 Metabolism Assays 
Lymphocytes were isolated from ndLN and TIL of Foxp3Cre-YFP and Nrp1L/LFoxp3Cre-YFP 
mice. To assess mitochondrial mass and function, cells were stained with MitoTracker 
FM and TMRE respectively. To visualize hypoxic cells within the tumor, mice were 
injected with 2mg pimonidazole in 100uL PBS IV 1 hour prior to sacrifice and staining 
was done using Hypoxiprobe 549 at 1:400 for histology and 1:1000 for flow cytometry. 
For metabolic function assays, cells were loaded on a Cell-Tak coated Seahorse culture 
plate (60,000-100,000 cells per well) in DMEM supplemented with 1% BSA, 25mM 
glucose, 1mM pyruvate, and 2mM glutamine and were analyzed on a Seahorse XFe96 
(Agilent). Basal extracellular acidification (ECAR) and oxygen consumption (OCR) rates 
were taken for 30 minutes prior to stimulation with oligomycin (2uM), FCCP (0.5uM), 2-
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DG (100mM) and rotenone/antimycin A (100uM) to determine maximum respiratory 
values.  
2.2.9 Bisulfite Sequencing 
CD4+Foxp3– and CD4+Foxp3+ T cells were sorted from ndLN or TIL of 
Foxp3Cre=YFP or Nrp1L/LFoxp3Cre-YFP mice on day 12 after B16 inoculation. Bisulfite 
conversion was performed on half the samples (with the other half as unconverted 
controls) using either the Zymo EZ DNA Methylation Kit (#D5001) on gDNA for 14 hours 
or using the Zymo EZ DNA Methylation-Direct Kit (#D5020) directly on cells as outlined 
in the protocol. Methyl-specific PCR (primers below) was performed on samples, prior to 
TOPO cloning (10+ colonies picked per sample) and minipreps (Clontech Nucleospin 
Plasmid EasyPure Kit). A portion of the miniprep product was digested with EcoR1 to 
verify band size. 200ng of the miniprep products were resuspended in 10uL with 2.5uL 
of primers T7 (forward) or SP6 (reverse), both kept at 20mM, and were sent for Sanger 
sequencing. Analysis was done using DNAStar. 
Amp 1/2 Untreated Primer (f): GAGGCTGACATTCCAGAGCCAGC 
Amp 1/2 Untreated Primer (r): GAGGACCTGAATTGGATATGGTCTGTCTAG   
Amp 1/2 Treated Primer (f): CTAACATTCCAAAACCAACAAAAAACC 
Amp 1/2 Treated Primer (r): GGATTTGAATTGGATATGGTTTGTTTAG 
T7 Primer: GGC TTG TCG ACA TTA ATA CGA CTC ACT ATA GGG 
SP6 Primer: GGC ATT TAG GTG ACA CTA TAG 
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2.2.10 Quantification and statistical analysis 
Statistics were performed using Prism v6.07. Students t-tests were used in to 
determine statistical significance between groups from flow cytometry analysis. Kaplan 
Meier was used to determine significance between tumor associated survival. Two-way 
ANOVA was used to determine significance between groups over time in tumor growth 
experiments. “n” represents the number of mice used in the experiment, with the 
number of individual experiments listed in the legend. Graphs show individual samples. 
Samples are shown with the mean with or without error bars showing the SEM. 
Significance was defined as p=0.05. 
2.2.11 Data and software availability (Chapter 3) 
The RNASeq datasets from Chapter 3 have been deposited in the Gene 
Expression Omnibus (GEO) under code GSE97939. 
2.3 Resources 





CD4 Biolegend GK1.5 
CD8 Biolegend YTS156.7.7 
TCRβ Biolegend H57-597 
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Thy1.1  Biolegend OX-7 
Thy1.2 Biolegend 30-H12 
Foxp3 Biolegend FJK-16s 
IFNγ Biolegend XMG1.2 
Nrp1 Biolegend 3E12 
ICOS Biolegend C398.4A 
pAKT Cell Signaling D9E 
pSTAT1 BD Biosciences 4a 
pSTAT4 BD Biosciences 38 
CD3 (human) Biolegend HIT3a 
CD4 (human) eBioscience RPA-T4 
CD25 (human) Biolegend BC96 
CD127 (human) Biolegend A019D5 
Foxp3 (human) eBioscience PCH101 
IFNγR (human) eBioscience GIR-208 
Nrp1 (human) Abcam EPR3113 
Hif1α (human/mouse) R&D 241812 
PD1 (blocking) In house G4 
Arm. Hamst. IgG Bioxcell BE0091 
Rat IgG2a Bioxcell 2A3 
CD8 (depleting) Bioxcell 53-6.72 
Chemicals, Peptides, and Recombinant Proteins 
Diptheria Toxin Sigma D0564 
Sema4aIg In house In house 
Critical Commercial Assays 
SMARTer® UltraTM Low Input 
RNA Kit for Sequencing - v3 
 Clontech  634850 





RNASeq GEO GSE97939 
Experimental Models: Cell Lines 
B16.F10 M.J. Turk Dartmouth College 
MC38 J.P. Allison MD Anderson 
Experimental Models: Organisms/Strains 
Foxp3Cre-YFP A.Y. Rudensky Memorial Sloan Kettering 
Nrp1L/L D. Cheresh UC San Diego 
Foxp3DTR-GFP A.Y. Rudensky Memorial Sloan Kettering 
RosaL-Tom-L GFP Jackson Labs 007576 
Ifng–/– Jackson Labs 002287 
Ifngr1–/– Jackson Labs 003288 
Ifngr1L/L Jackson Labs 025394 
Foxp3–/– A.Y. Rudensky Memorial Sloan Kettering 
Software and Algorithms 
mSigDB Subramanian et al 2005 http://www.pnas.org/content/102/43/1
5545.abstract 
Fisher Fisher, RA 1925 http://www.haghish.com/resources/m
aterials/Statistical_Methods_for_Rese
arch_Workers.pdf 
Picard Broad Institute https://broadinstitute.github.io/picard/ 






3.0   INTERFERON-γ DRIVES TREG FRAGILITY TO PROMOTE ANTI-TUMOR 
IMMUNITY 
 
Data within this chapter were compiled and published in Cell in 2017 in the 
following manuscript:  
Overacre-Delgoffe AE, Chikina M, Dadey RE, Yano H, Brunazzi EA, Shayan G, Horne 
W, Moskovitz JM, Kolls JK, Sander C, Shuai Y, Normolle DP, Kirkwood JM, Ferris RL, 
Delgoffe GM, Bruno TB, Workman CJ, Vignali DAA. “Interferon-γ drives Treg fragility to 




Regulatory T cells (Tregs) are a barrier to anti-tumor immunity. Neuropilin-1 (Nrp1) is 
required to maintain intratumoral Treg stability and function but is dispensable for 
peripheral homeostasis. Treg-restricted Nrp1 deletion results in profound tumor 
resistance due to Treg functional fragility.  Drivers of Treg fragility, the mechanistic basis 
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of Nrp1-dependency, and relevance for human cancer and immunotherapy remain 
unknown.  I show that a high percentage of intratumoral NRP1+ Tregs correlates with 
poor prognosis in melanoma and HNSCC.  Using a mouse model of melanoma where 
Nrp1-deficient (Nrp1–/–) and wild-type (Nrp1+/+) Tregs could be assessed in a competitive 
environment, I found that a high proportion of intratumoral Nrp1–/– Tregs produce 
interferon-γ (IFNγ), which drives the fragility of surrounding WT Tregs, boosts anti-tumor 
immunity, and facilitates tumor clearance.  
 
3.2 INTRODUCTION 
Regulatory T cells (Tregs), characterized by their expression of the forkhead box 
transcription factor, Foxp3, are required to maintain immune homeostasis and prevent 
excessive tissue damage 29, 39, 103, 104. Humans that lack a functional Treg population 
develop a lethal autoimmune disorder, termed Immune dysregulation, 
Polyendocrinopathy, Enteropathy, X-linked (IPEX) syndrome, which can be 
recapitulated in mice through Foxp3 deletion.  While Tregs are required to limit 
autoimmunity and maintain immune regulation, they can be deleterious in cancer 
through suppression of anti-tumor immunity 105, 106, 107. Indeed, high numbers of Tregs 
and a low CD8+ T cell:Treg ratio are considered poor prognostic factors for many tumor 
types, including melanoma, head and neck squamous cell carcinoma (HNSCC), ovarian 
cancer and colorectal carcinoma 37, 108, 109, 110, 111.  Although targeting intratumoral Tregs 
could be an effective therapeutic approach for multiple tumor types, perturbation of 
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peripheral Treg number or function could lead to life-threatening autoimmune or 
inflammatory complications.  Therefore, identifying pathways that could be targeted to 
selectively undermine intratumoral Tregs is essential.  
It has been previously shown that Neuropilin-1 (Nrp1) is expressed by ~90% of 
tumor infiltrating Tregs in mouse models of cancer and is critical for their function in the 
tumor microenvironment 43.  Indeed, mice with a Treg-restricted deletion of Nrp1 are 
highly resistant to B16 melanoma, which is normally refractory to immune-mediated 
clearance, yet remarkably do not exhibit any autoimmune or inflammatory disease. 
Although Nrp1-deficient Tregs have been previously described as ‘unstable’, due to their 
loss of function 43, previous studies and data included here clearly show that they retain 
Foxp3 expression.  Thus, this phenotype is now referred to as Treg ‘fragility’ consistent 
with their retention of Foxp3 expression yet loss of function ex vivo (as exhibited by loss 
of suppressive activity in vitro) and tumor tolerance in vivo (as exhibited by tumor 
growth reduction/clearance).  While it has been previously shown that Nrp1 plays a role 
in maintaining intratumoral Treg function, many questions remain including the fate of 
these fragile Tregs and their contribution to anti-tumor immunity, the drivers of Treg 
fragility, the expression, contribution, and impact of NRP1 on human intratumoral Tregs, 
and the broader implications for Treg function and cancer immunotherapy.  
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3.3 RESULTS 
3.3.1 Increased NRP1 expression on Tregs in human cancer 
While Nrp1 has been shown to prevent Treg fragility in mice, its presence and role in 
human Tregs remains unclear.  Previous studies have been controversial, with some 
suggesting peripheral human Tregs do not express NRP1 while other suggest that 
NRP1+ Tregs are potent suppressors 22, 112, 113, 114, 115, 116, 117, 118.  Indeed, very few human 
Tregs in peripheral blood lymphocytes (PBL) from healthy donors express NRP1 (Fig. 1A 
and B).  Remarkably, most patients with metastatic melanoma and head and neck 
squamous cell carcinoma (HNSCC) possessed a reasonably high percentage of 
intratumoral NRP1+ Tregs (Fig. 1A and B).  This varied considerably from 3-90% in 
melanoma and 35-90% in HNSCC.  The percentage of NRP1+ Tregs in PBL was also 
substantially enhanced.  Interestingly, NRP1 expression in intratumoral Tregs appeared 




Figure 1: Decreased Nrp1 expression leads to tumor regression and enhanced survival. 
 (A-C) Flow cytometry analysis of human Tregs. Lymphocytes were harvested from PBL of healthy donors 
(n=8) or from PBL of healthy donor and TIL of Head and Neck Squamous Cell Carcinoma (HNSCC) and 
metastatic melanoma (3-5 experiments, n=16-23) and frozen or stained fresh. Frozen TIL and PBL were 
thawed and stained directly without stimulation. (D-G) Mice breeding scheme and tumor growth curves. 
Foxp3Cre-YFP/Cre-YFP, Nrp1L/LFoxp3Cre-YFP/Cre-YFP, Nrp1L/LFoxp3Cre-YFP/DTR-GFP, Foxp3DTR-GFP/DTR-GFP, and 
Foxp3DTR-GFP/+ mice were injected with B16.F10 melanoma tumor cells ID on day 0. Tumor growth was 
measured with digital calipers every three days. Mice were removed from study when tumor growth 
reached a diameter of 2cm in any direction or when necrosis was observed, and survival plots were 
generated (4 experiments, n=9-18). (F-G) Mice breeding scheme and tumor growth curves. Foxp3DTR-
GFP/DTR-GFP, and Foxp3DTR-GFP/+ mice were treated with 100µg Diptheria Toxin IP every three days starting 
on day 7. (H) Microsuppression assays. Tregs were isolated on day 12 post B16 injection from ndLN and 
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TIL of Foxp3Cre-YFP/Cre-YFP, Nrp1L/LFoxp3Cre-YFP/Cre-YFP, and Nrp1L/LFoxp3Cre-YFP/DTR-GFP mice and cultured with 
effector T cells and APCs for 72 hours in a classical microsuppression assay. Tregs were pooled from 3 
mice with 5-6 mice per group per experiment. Proliferation was measured and percent suppression was 
calculated as described in methods. Data represent 3-5 (A-C), 4 (D-G), or 3 (H) independent experiments. 
Error bars represent the mean ± SEM.  Students unpaired t test (Fig. 1B, H), 2 way ANOVA (Fig. 1E, G), 
and Kaplan-Meier tests (Fig. 1E, G) were used (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). 
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3.3.2 Nrp1–/– Tregs block wild type Treg function and promote anti-tumor immunity 
It has been previously shown that anti-Nrp1 substantially limits the growth of a B16 
mouse model of human melanoma 43.  Given the heterogeneous nature of NRP1 
expression on human tumor infiltrating Tregs, where only a proportion express NRP1, I 
questioned what impact Nrp1 loss on only a proportion of mouse Tregs might have on 
the function of the remaining wild-type (WT) counterparts, and by extension anti-tumor 
immunity and tumor growth.  Also, as Nrp1-deficient Tregs show a reduction in 
suppressive function but also an increase in effector phenotype 43, I questioned whether 
these cells had an active role in re-shaping the tumor microenvironment, or whether 
reduced tumor growth was instead due to reduction of a major suppressive cell 
population.   
Foxp3 is on the X chromosome and is thus subject to X inactivation 119, 120, 121, 
rendering only one allele active in each Treg.  Consequently in heterozygous 
Nrp1L/LFoxp3Cre-YFP/DTR-GFP female mice, 50% of Tregs have a Cre-mediated deletion of 
Nrp1, are marked with YFP [herein referred to as Nrp1–/– Tregs] and exhibit functional 
fragility, and the other 50% express DTR-GFP and are WT Tregs, as they carry the 
Nrp1L/L allele but not Foxp3Cre-YFP [herein referred to as Nrp1+/+ Tregs] (Fig. 1D).  I first 
assessed tumor growth in heterozygous Nrp1L/LFoxp3Cre-YFP/DTR-GFP female mice, with 
Nrp1L/LFoxp3Cre-YFP/Cre-YFP [all Tregs are Nrp1–/–] and Foxp3Cre-YFP/Cre-YFP [all Tregs are 
WT/Nrp1+/+] female mice as controls.  Strikingly, Nrp1L/LFoxp3Cre-YFP/DTR-GFP mice 
exhibited dramatically reduced tumor growth, enhanced survival, and increased 
intratumoral lymphocyte and CD8+ T cell number, phenocopying Nrp1L/LFoxp3Cre-YFP/Cre-
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YFP mice (Fig. 1E and Fig. 2A) 43.  This occurred despite the presence of Nrp1+/+ Tregs in 
similar numbers to Nrp1–/– Tregs in the tumor (Fig. 2A).  A previous study had suggested 
that the absence of Nrp1 leads to reduced influx of Tregs into certain tumor types 122.  
However, there did not seem to be a significant difference in the number of intratumoral 
Nrp1–/– versus Nrp1+/+ Tregs, even in Nrp1L/LFoxp3Cre-YFP/DTR-GFP mice (Fig. 2A).  One 
might also argue that the Nrp1L/LFoxp3Cre-YFP mutation causes a basal inflammatory 
state that impacts the establishment of a tumor mass.  To rule this out and any potential 
impact Nrp1 loss may have on Treg development, migration and function, the impact of 
Nrp1 temporal deletion in Tregs following the establishment of B16 tumor growth was 
determined.  Nrp1L/LFoxp3CreERT2, but not Foxp3CreERT2, mice exhibited substantially 
reduced tumor growth following Nrp1 deletion induced by daily tamoxifen treatment on 
Days 7-11 (Fig. 2B-C).   
To rule out the possibility that the inability of Nrp1+/+ Tregs to block anti-tumor 
immunity and tumor clearance was due to their reduced number in heterozygous 
Nrp1L/LFoxp3Cre-YFP/DTR-GFP mice, I also assessed tumor growth in heterozygous 
Foxp3DTR-GFP/+ female mice in which diphtheria toxin (DT) treatment reduced peripheral 
and intratumoral Treg number by approximately half (Fig. 1F and Fig. 2D). In stark 
contrast to tumor growth in heterozygous Nrp1L/LFoxp3Cre-YFP/DTR-GFP mice, DT-treated 
heterozygous Foxp3DTR-GFP/+ mice exhibited tumor growth that was indistinguishable 
from the untreated control mice (Fig. 1G).  While Foxp3DTR-GFP/DTR-GFP mice treated with 
DT largely cleared their tumors, they ultimately succumbed to autoimmunity due to an 
absence of Tregs in contrast to heterozygous Nrp1L/LFoxp3Cre-YFP/DTR-GFP and 
Nrp1L/LFoxp3Cre-YFP/Cre-YFP female mice that never exhibited an autoimmune or 
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inflammatory phenotype (Fig. 1D and 1E, and data not shown) 43.  Taken together, my 
data suggest that if half the Tregs are depleted tumors grow unrestrained, as the reduced 
number of WT Tregs are still capable of blocking anti-tumor immunity. In contrast, if half 
the Tregs lose Nrp1, tumors are controlled, suggesting that Nrp1–/– Tregs are playing an 
active role in re-shaping the tumor microenvironment. I hypothesized that Nrp1–/– Tregs 
not only lost their suppressive activity but may also negatively impact the function of 
surrounding intratumoral Nrp1+/+ Tregs.  In order to assess this possibility, I determined 
the suppressive capacity of Nrp1+/+ (GFP+) and Nrp1–/– (YFP+) Tregs from 
Nrp1L/LFoxp3Cre-YFP/DTR-GFP heterozygous and control mice using a microsuppression 
assay 101.  While all Treg populations isolated from non-draining lymph nodes (ndLN) 
were equally capable of suppressing effector T cells (Fig. 1H), Nrp1–/– Tregs isolated from 
homozygousNrp1L/LFoxp3Cre-YFP/Cre-YFP and heterozygous Nrp1L/LFoxp3Cre-YFP/DTR-GFP 
tumors lacked suppressive activity (Fig. 1H). Interestingly, intratumoral Nrp1+/+ Tregs 













Figure 2: Temporal Nrp1 deletion leads to reduced tumor growth. 
(A) Cell numbers in the tumor. Lymphocytes were isolated from TIL of Foxp3Cre-YFP/Cre-YFP, 
Nrp1L/LFoxp3Cre-YFP/Cre-YFP, and Nrp1L/LFoxp3Cre-YFP/DTR-GFP mice, stained and quantified for cell numbers 
(n=2-6). (B) Tumor growth curve. Foxp3CreERT2-GFPRosaLSL-YFP or Nrp1L/LFoxp3CreERT2-GFPRosaLSL-YFP mice 
were injected with B16.F10 ID on day 0 and treated with Tamoxifen on days 7-11. Tumors were 
measured every 3 days (n=5-11). (C) Analysis of temporal deletion of Nrp1. Foxp3CreERT2-GFPRosaLSL-YFP or 
Nrp1L/LFoxp3CreERT2-GFPRosaLSL-YFP mice were bled on days indicated and stained. Mice were treated with 
Tamoxifen on days 1-5 (n=3). (D) Analysis of Treg depletion with DT treatment. Lymphocytes were 
isolated from ndLN and TIL of Foxp3DTR-GFP/DTR-GFP, Foxp3DTR-GFP/DTR-GFP + DT, and Foxp3DTR-GFP/+ + DT 
mice (n=3-6). Data represent 2-4 independent experiments. Student unpaired t test (S1A), 2-way ANOVA 
and Kaplan-Meier tests (S1B) were used. (*p < 0.05, ****p<0.0001). 
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It is possible that Nrp1–/– Tregs impact the tumor microenvironment by losing 
Foxp3 and becoming so-called ex-Tregs with an altered functional phenotype 71, 73, 123. 
Ex-Tregs have been previously reported in lymphopenia and diabetes. Around ~10-20% 
of Tregs lost Foxp3 and became pathogenic in nature. Still, other groups performed 
similar assays and found that Foxp3 was very stable in vivo 64. The key distinctions 
between these two contradicting ideas were the disease and mouse models. First, 
exTregs were identified in settings of autoimmunity (NOD mice for example), whereas the 
lack of exTregs was reported in steady state conditions or in infection. Second, exTregs 
were uncovered utilizing a BAC transgenic mouse while subsequent studies showing a 
stable lineage utilized an inducible Cre system. This is a critical distinction as BAC 
transgenic mice sometimes display unfaithful promoter expression and also label all 
cells from early in development, leading to confounding results if Foxp3 is transiently 
upregulated during this time. By using an inducible Cre, one can ‘tag’ the cells after they 
have developed and moved into the periphery, presumably allowing one to label 
mature, stable Tregs.  
 I analyzed Foxp3 fate mapping mice in which Tregs either possessed (Foxp3Cre-
YFPRosaL-Tom-L-GFP) or lacked Nrp1 expression (Nrp1L/LFoxp3Cre-YFPRosaL-Tom-L-GFP) (Fig. 
3A). In this mouse model, non-Tregs are Tomato+GFP–YFP–, Foxp3+ Tregs are Tomato–
GFP+YFP+ and Foxp3– ex-Tregs are Tomato–GFP+YFP–. Interestingly, there were very 
few (<5%) ex-Tregs present in the periphery or in the tumor, regardless of Nrp1 
expression (Fig. 3B and C). These data suggest that the absence of Nrp1 does not 
affect Foxp3 expression and does not result in the generation of ex-Tregs. 
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Previous reports have shown that Tregs can display alternative functions in vivo while 
maintaining Foxp3 expression 85, 124. Two hallmarks of Treg fragility are elevated pAkt 
and reduced ICOS expression 43. Elevated pAkt and reduced ICOS were observed in 
Nrp1–/– Tregs in Nrp1L/LFoxp3Cre-YFP/Cre-YFP mice and Nrp1L/LFoxp3Cre-YFP/DTR-GFP 
heterozygous mice relative to Nrp1+/+ Tregs in Foxp3Cre-YFP/Cre-YFP mice as expected (Fig. 
3D and E). However, elevated pAkt and, to a lesser extent, reduced ICOS was also 
observed in Nrp1+/+ Tregs in Nrp1L/LFoxp3Cre-YFP/DTR-GFP heterozygous mice.  Taken 
together, these data suggest that Nrp1–/– Tregs have a negative impact on the 


















Figure 3: Nrp1–/– Tregs maintain Foxp3 expression. 
exTreg analysis. (A-C) Lymphocytes were isolated from ndLN, dLN, and TIL of Foxp3Cre-YFP/Cre-YFPRosaL-
Tom-L GFP and Nrp1L/LFoxp3Cre-YFP/Cre-YFPRosaL-Tom-L GFP mice and stained (n=3-5). (D-E) Lymphocytes were 
isolated from TIL of Foxp3Cre-YFP/Cre-YFP, Nrp1L/LFoxp3Cre-YFP/Cre-YFP, Nrp1L/LFoxp3Cre-YFP/+ mice and stained. 
Tregs from Nrp1
L/LFoxp3Cre-YFP/+ mice were stained with Foxp3 and Nrp1+ and Nrp1– Tregs were 
distinguished as YFP+Foxp3+ (Nrp1–) and YFP–Foxp3+ (Nrp1+). This was also verified by Nrp1 staining 
(n=5). Data represent 2-3 independent experiments. Student unpaired t test was used. (ns, not significant, 
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).  
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3.3.3 Fragile and wild type Tregs have a reciprocal impact on their transcriptome 
I next used transcriptomic analysis of Nrp1+/+ and Nrp1–/– Tregs from Foxp3Cre-YFP/Cre-YFP, 
Nrp1L/LFoxp3Cre-YFP/Cre-YFP and Nrp1L/LFoxp3Cre-YFP/DTR-GFP mice to evaluate the cell 
intrinsic and extrinsic impact of Nrp1 loss (Fig. 4). Significant alterations in the Treg 
transcriptome were observed between Nrp1+/+ and Nrp1–/– Tregs. Principal Component 
Analysis (PCA) based on differentially expressed genes clearly separated Teff and Tregs 
based on both location and genotype.  Interestingly, intratumoral Nrp1+/+ and Nrp1–/– 
Tregs from heterozygous Nrp1L/LFoxp3Cre-YFP/DTR-GFP mice were similar to each other and 
yet distinct from their genotypically identical counterparts from control Foxp3Cre-YFP/Cre-
YFP and Nrp1L/LFoxp3Cre-YFP/Cre-YFP mice (Fig. 5A).   
Pathway analysis highlighted a potential role for IFNγ/IL-12-related transcriptional 
programs. Of particular interest was an increase in Ifng and its targets in Nrp1–/– Tregs in 
Nrp1L/LFoxp3Cre-YFP/Cre-YFP and Nrp1L/LFoxp3Cre-YFP/DTR-GFP as well as in Nrp1+/+ Tregs in 
Nrp1L/LFoxp3Cre-YFP/DTR-GFP mice (Fig. 5B-C), implicating a role for the IFNγ pathway in 
modulating Treg function and function in the tumor microenvironment. When Treg 
signature genes were assessed wherein it became evident that all four populations 
were district and yet bore a transcriptional relationship (Fig. 6A-D).  These data suggest 
that Nrp1+/+ and Nrp1–/– Tregs in heterozygous Nrp1L/LFoxp3Cre-YFP/DTR-GFP mice impact 

















Figure 4: RNASeq sorting scheme. 
RNASeq double sorting scheme. Tregs were isolated from ndLN and TIL of Foxp3
Cre-YFP/Cre-YFP, 
Nrp1L/LFoxp3Cre-YFP/Cre-YFP, and Nrp1L/LFoxp3Cre-YFP/DTR-GFP mice and checked for purity. Cells were either 
single or double sorted. No significant difference was noted between single or double sorted samples. 




Figure 5: Nrp1 alters the Treg transcriptome. 
RNASeq analysis. (A-C) Tregs were purified based on CD4+, and GFP or YFP expression from Foxp3Cre-
YFP/Cre-YFP, Nrp1L/LFoxp3Cre-YFP/Cre-YFP, and Nrp1L/LFoxp3Cre-YFP/DTR-GFP mice on D12, cDNA and libraries were 
generated using the Clontech SmartER Ultra-Low and Illumina Nextera XT Library Prep kits. Samples 
were normalized to 2nM and sequenced on a NextSeq500. (A) Differentially expressed genes are 
determined by the genes that have q-value of 0.2 between any two of the four Treg groups in the TIL. PCA 
was computed using the “prcomp()” R functions using the normalized voom data restricted to the same 
differentially expressed genes as shown in figure. (B-C) Significant genes were cross-referenced with 
those that were annotated to “plasma membrane” or “extracellular part” in the Cellular Component Gene 
Ontology. The Gene Ontology annotations were obtained from mSigDB. A number of genes associated 
with the Ifng/Il12/Il18 pathways were upregulated in the Nrp1–/– samples. Data represent 5 independent 























Figure 6: Nrp1–/– display an altered Treg signature. 
RNASeq analysis. Tregs were isolated from ndLN and TIL of Foxp3
Cre-YFP/Cre-YFP, Nrp1L/LFoxp3Cre-YFP/Cre-YFP, 
and Nrp1L/LFoxp3Cre-YFP/DTR-GFP mice and checked for purity. (A) Volcano plots. (B) Global heatmap. All 
genes that passed a threshold of q-value FDR <0.2 are shown. (C) Treg signature gene heatmap. 
Green/red coloring represents genes that are upregulated/downregulated in Tregs. (D) Bar chart of top 
differentially expressed pathways. Data represent 5 experiments.  
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While previous reports have suggested that a small subset of Tregs produce IFNγ 
during inflammation 125, 126, 127, the expression of IFNγ by Tregs in tumors and its impact 
on their suppressive function remains unclear. Using flow cytometry, I found that there 
was increased expression of IFNγ by Nrp1–/– Tregs in both Nrp1L/LFoxp3Cre-YFP/Cre-YFP and 
Nrp1L/LFoxp3Cre-YFP/DTR-GFP mice (Fig. 7A-B).  Interestingly, an increased percentage of 
Nrp1+/+ Tregs from Nrp1L/LFoxp3Cre-YFP/DTR-GFP mice also expressed IFNγ.  Interferon-γ 
receptor 1 (IFNγR) expression showed an elevated trend in Nrp1–/– Tregs in 
Nrp1L/LFoxp3Cre-YFP/Cre-YFP mice, and both Nrp1–/– and Nrp1+/+ Tregs in Nrp1L/LFoxp3Cre-
YFP/DTR-GFP heterozygous mice (Fig. 7B).  In order to determine whether modulation of 
IFNγ and IFNγR expression also occurred following blockade of the Nrp1:Sema4a axis, 
I treated B16 tumor-bearing mice with Sema4aIg 43. Indeed, Sema4aIg treatment 
decreased tumor size, and led to an unstable Treg phenotype as assessed by increased 
IFNγ production and higher IFNγR expression (Fig. 7C-E). In addition to increases in 
IFNγ production and IFNγR expression, several type 1 helper T cell markers were 
upregulated in Nrp1–/– Tregs, such as Tbet, Cxcr3, and Eomes (Fig. 8A–F) as well as 
downstream pSTAT1 in Nrp1–/– Tregs from Nrp1L/LFoxp3Cre-YFP/DTR-GFP mice and pSTAT4 















Figure 7: Nrp1–/– Tregs display increased IFNγ in the tumor microenvironment. 
Flow cytometry analysis. (A-B) Foxp3Cre-YFP/Cre-YFP, Nrp1L/LFoxp3Cre-YFP/Cre-YFP, and Nrp1L/LFoxp3Cre-YFP/DTR-
GFP mice were injected with B16.F10 melanoma tumor cells ID on day 0 and sacrificed on day 12.  
Lymphocytes were isolated from ndLN and TIL of mice noted, stimulated and stained for IFNγ and IFNγR. 
(n=8-18). (C-E) C57BL/6 mice were injected with B16.F10 melanoma tumor cells ID on day 0. Mice were 
treated with either Sema4aIg or IgG1 every 3 days until sacrifice starting on day 5 (400ug, 200ug, 200ug, 
200ug). (C) Tumors were measured on day 12 for prior to sacrifice (n=10-25). (D) Lymphocytes were 
isolated from ndLN and TIL, stimulated and stained for IFNγ (n=5-13). (E) Lymphocytes were isolated 
from ndLN and TIL, and stained for IFNγR (n=5). Data represent 3-4 independent experiments. Student 

















Figure 8: Nrp1 loss leads to an increase in TH1 markers. 
Flow cytograms of markers indicated. (A-H) Lymphocytes were isolated from ndLN, dLN, or TIL of 
Foxp3Cre-YFP/Cre-YFP, Nrp1L/LFoxp3Cre-YFP/Cre-YFP, Nrp1L/LFoxp3Cre-YFP/+ mice and stained. Tregs from 
Nrp1L/LFoxp3Cre-YFP/+ mice were stained with Foxp3 and Nrp1+ and Nrp1– Tregs were distinguished as 
YFP+Foxp3+ (Nrp1–) and YFP–Foxp3+ (Nrp1+) (n=5-15). (I) Foxp3Cre-YFP/Cre-YFP and Nrp1L/LFoxp3Cre-YFP/Cre-
YFP mice were injected with B16 on day 0 and treated with isotype or anti-CD8 (n=4-7). Lymphocytes were 
isolated from TIL and stained. (J-K) Tregs were isolated from Foxp3
Cre-YFP/Cre-YFP and Nrp1L/LFoxp3Cre-YFP/Cre-
YFP mice and stimulated in hypoxia or normoxia for 3 days and stained (n=6).  Data represent 3-6 
independent experiments. Student unpaired t test was used. (ns, not significant, *p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001).  
 52 
Surprisingly, I found that the majority of the IFNγ+ cells in the TIL of 
Nrp1L/LFoxp3Cre-YFP and Nrp1L/LFoxp3Cre-YFP/DTR-GFP were Tregs (Fig. 9A) and that the total 
percentage of IFNγ+ cells in TIL was small in the absence of Treg-restricted Nrp1 
deletion (Fig. 9B), raising the possibility that IFNγ production may be a dominant feature 
of Treg fragility and thus could be affecting surrounding cells in the tumor 
microenvironment including Nrp1+/+ Tregs. 
While my data show that Tregs produced significant amounts of IFNγ in 
Nrp1L/LFoxp3Cre-YFP and Nrp1L/LFoxp3Cre-YFP/DTR-GFP mice, I could not rule out the 
possibility that IFNγ production by fragile Tregs was initially triggered, or potentiated by, 
the altered tumor microenvironment. Indeed, tumor size is greatly reduced and 
lymphocyte infiltration increased in Nrp1L/LFoxp3Cre-YFP and Nrp1L/LFoxp3Cre-YFP/DTR-GFP 
mice (Fig. 1E and Fig. 2A). In order to address this possibility, I blocked the anti-tumor 
immune response and prevented tumor shrinkage by depleting CD8+ T cells (using anti-
CD8) in B16 tumor bearing mice, and assessed Treg phenotype and function. I found 
that CD8+ T cell depletion had no effect on the suppressive capacity in Nrp1L/LFoxp3Cre-
YFP and Nrp1L/LFoxp3Cre-YFP/DTR-GFP mice. Indeed, Nrp1–/– Tregs exhibited increased IFNγ 
and Tbet protein expression along with reduced in suppressive capacity in an in vitro 
suppression assay, suggesting that Treg fragility due to Nrp1 loss is primarily due to a 
cell intrinsic mechanism rather than an extrinsic environmental effect due to increased 
CD8+ T cell infiltration, the ensuing anti-tumor response, and tumor size (Fig. 8I-J and 
Fig. 9C-D).  However, a role for CD8+ T cell-derived IFNγ in promoting Treg fragility in 
this system cannot be ruled out. 
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Although cell-intrinsic processes downstream of Nrp1 loss appeared to drive Treg 
fragility, it is still possible that cell-extrinsic, environmental factors facilitated intratumoral 
Treg fragility.  Further analysis of my RNAseq data highlighted enhanced expression of 
Hif1a (hypoxia-inducible factor 1 alpha) in Nrp1–/– compared to Nrp1+/+ intratumoral Tregs 
(Fig. 9E). Indeed, the percentage of Hif1α+ Nrp1–/– intratumoral Tregs and Hif1α protein 
expression within those Tregs was higher than their Nrp1+/+ counterparts (Fig. 9F).  
Interestingly, Hif1α has been shown to be upregulated by Akt signaling which in turn led 
to increased IFN-γ production by Tregs 128, 129.  As Hif1α is upregulated in hypoxic 
conditions, I wondered whether hypoxia was capable of inducing Treg fragility, analogous 
to the environment in which intratumoral Tregs reside. Remarkably, LN-derived Tregs from 
a naïve mouse showed increased IFN-γ and Tbet expression, and an elevated trend in 
Hif1α expression while retaining Foxp3 expression after being cultured for 3 days in 
hypoxic versus normoxic conditions (Fig. 9G and Fig. 8K and L). These data suggest 



















Figure 9: Hypoxia sensitizes intratumoral Tregs to IFNγ-mediated fragility. 
 (A-B) Flow cytometry of cell populations. Foxp3Cre-YFP/Cre-YFP, Nrp1L/LFoxp3Cre-YFP/Cre-YFP, and 
Nrp1L/LFoxp3Cre-YFP/DTR-GFP mice were injected with B16.F10 melanoma tumor cells ID on day 0 and 
sacrificed on day 12.  Lymphocytes were isolated from TIL of mice noted, stimulated and stained for IFNγ 
(n=5). (C-D) Flow cytometry and suppression assay after CD8 depletion. Mice were treated with anti-CD8 
or isotype (200ug) every 3 days starting on day 5. Tumor size was measured on day of sacrifice (D12), 
lymphocytes were isolated from TIL of mice noted, stimulated, and stained for IFNγ (n=7-10). (E) 
RNASeq analysis. Lymphocytes were isolated from mice noted and used in a microsuppression assay. 
(F) Flow cytometry analysis. Tregs were purified, processed, and analyzed as in Fig. 2 (n=5). Heatmap 
includes genes previously shown to be positive or negative regulators in the Hif1α pathway. Pathway 
analysis includes all genes in pathway. (G) Flow cytometry analysis after Tregs were cultured in hypoxia. 
Foxp3Cre-YFP/Cre-YFP and Nrp1L/LFoxp3Cre-YFP/Cre-YFP mice were injected with B16.F10 melanoma tumor cells 
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ID on day 0 and sacrificed on day 12.  Lymphocytes were isolated from ndLN and TIL and stained for 
Hif1α (n=10). (H) Tregs were isolated from LN of Foxp3Cre-YFP/Cre-YFP mice, stimulated for 3 days in hypoxia 
or normoxia, and stained (n=4-6).   Data represent 2-5 independent experiments. Student unpaired t test 
was used. (*p<0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).  
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3.3.4 IFNγ is required and sufficient to drive intratumoral Treg fragility 
In order to test whether Nrp1–/– Tregs could directly impact the function of Nrp1+/+ 
Tregs, and if this was mediated by IFNγ, I co-cultured ndLN- or tumor-derived Nrp1+/+ 
Tregs from either Thy1.1 Foxp3Cre-YFP or Ifngr1–/–Foxp3Cre-YFP mice (Tregs which lack the 
IFNγ receptor) with Nrp1–/– Tregs from Thy1.2 Nrp1L/LFoxp3Cre-YFP mice prior to assessing 
their regulatory activity in a microsuppression assay (Fig. 10A).  All cell populations 
were also cultured alone under the same conditions as controls, and as expected, Treg 
populations cultured alone exhibited the expected suppressive capacity (Fig. 1H 
compared with Fig. 10B, left side columns).  Note that APCs were not included in the 
72h pre-culture prior to the Treg microsuppression assay. Interestingly, TIL-derived 
Nrp1+/+ Tregs that were co-cultured with tumor-derived Nrp1–/– Tregs lost their ability to 
suppress effector T cells, in contrast to ndLN-derived Tregs (Fig. 10B, right side 
columns). Loss of suppressive activity did not require cell-cell contact, but was 
dependent on IFNγR expression (Fig. 10B-D).  In order to confirm that IFNγ was the 
sole cytokine responsible for Nrp1+/+ Treg fragility following co-culture with Nrp1–/– Tregs, I 
co-cultured Nrp1+/+ and Nrp1–/– Tregs in the presence of different concentrations of anti-
IFNγ for 72 hours, and then assessed the suppressive capacity of the purified Nrp1+/+ 
Tregs in the absence of anti-IFNγ. IFNγ neutralization prevented the loss of tumor-















Figure 10: IFNγ reduces Treg suppression. 
In vitro cultures and suppression assays. (A, B) Tregs were isolated from ndLN and TIL of mice noted, 
stimulated with PMA and Ionomycin, cultured with IL-2 alone or with IL-2 and Nrp1–/– Tregs for 72 hours 
and used in a microsuppression assay in absence of cytokine (n=6-7). (C, D) Tregs were isolated and 
stimulated as in (A), cultured in the bottom of a transwell plate with IL-2 alone or with IL-2 and Nrp1–/– 
Tregs in the top well for 72 hours and used in a microsuppression assay in the absence of cytokine (n=6-
7). (E) Tregs were isolated from ndLN and TIL of Foxp3Cre-YFP/Cre-YFP mice, co-cultured with Nrp1–/– Tregs and 
IL-2 in the presence or absence of anti-IFNγ, re-sorted and used in a microsuppression assay in the 
absence of cytokine (n=6). (F) Tregs were isolated from ndLN and TIL of Foxp3Cre-YFP/Cre-YFP mice, treated 
with IL-2 and IFNγ for 72 hours, re-sorted and used in a microsuppression assay in the absence of 
cytokine (n=6). (G) Tregs were isolated from HNSCC PBL and TIL, cultured with IL-2 +/- IFNγ for 3 days, 
then used in a microsuppression assay in the absence of cytokine (n=2-14). Data represent 3-5 
experiments. Error bars represent the mean ± SEM. Student unpaired t test (A-D) and 2 Way Anova (E-
G) were used. (*p<0.05, **p <0.01, ****p <0.0001). 
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While previous studies have suggested that IL-12 can impact Treg suppression 
and induce IFNγ expression 130, 131, whether IFNγ has a direct effect on Tregs and if so 
what impact that might have in their function remains obscure.  In order to determine 
whether IFNγ was sufficient to limit suppressive capacity, I treated Nrp1+/+ Tregs from 
ndLN and TIL with IFNγ for 72 hours plus IL-2 in stimulating conditions prior to 
assessing their functional capacity in a microsuppression assay in the absence of 
cytokine. IFNγ substantially limited the suppressive capacity of TIL-derived, and to a 
lesser extent ndLN-derived, Nrp1+/+ Tregs in a dose-dependent manner (Fig. 10F). Given 
that IFNγ limits the function of murine Tregs, I asked whether IFNγ could also impact 
human Tregs and whether this was enhanced by the human tumor microenvironment.  
Indeed, intratumoral human Tregs showed an increased sensitivity to IFNγ in comparison 
to PBL Tregs when cultured with the cytokine 72 hours prior to assessment of their 
suppressive capacity in the absence of cytokine (Fig. 10G). Furthermore, intratumoral 
NRP1+ Tregs appeared to be less sensitive to the effects of IFNγ than NRP1– Tregs. 
The increased sensitivity of tumor- versus ndLN-derived Nrp1+/+ Tregs to Nrp1–/– 
Tregs appeared to correlate with IFNγR expression (Fig. 11A-B), and this effect was lost 
if Ifngr1–/– Tregs were used (Fig. 11C). Pre-treatment with IFNγ also induced IFNγ 
expression by WT Tregs but not Ifngr1–/– Tregs (Fig. 11D, and data not shown).  Taken 
together, these data suggest that IFNγ can undermine the function of murine and human 




Figure 11: Treg suppression is crippled by IFNγ. 
(A) Microsuppression assay. Tregs were isolated from ndLN and TIL of Foxp3
Cre-YFP mice, co-cultured with 
Nrp1–/– Tregs and IL-2 in the presence or absence of anti-IFNγ, resorted and used in a microsuppression 
assay (n=6). (B) Microsuppression assay. Tregs were isolated from the ndLN and TIL of Foxp3
Cre-YFP/Cre-YFP 
mice, treated with IL-12 and IL-2 for 72 hours, sorted based on Ifngr1 expression, co-cultured with Nrp1–/– 
Tregs for 72 hours with or without anti-IFNγ, and re-isolated for a microsuppression assay (n=3). (C) 
Microsuppression assay. Tregs were isolated from ndLN and TIL of Foxp3
Cre-YFP and Ifngr1–/–Foxp3Cre-YFP 
mice, treated with IL-2 and IFNγ for 72 hours, resorted and used in a microsuppression assay (n=3-4).  
(D) IFNγ MFI by flow cytometry. Tregs were isolated from TIL of Foxp3
Cre-YFP mice, treated with IFNγ and 
IL-2 for 72 hours, washed and stained (n=3). (E) Percent Nrp1+/+ and Nrp1–/– Tregs post transfer. Foxp3–/– 
mice were injected with 106 of a 50:50 mix of Nrp1+/+Thy1.1 and Nrp1–/–Thy1.2 Tregs on day 2 post-birth. 
B16.F10 was injected ID on day 28. Lymphocytes were isolated and stained (n=3). Data represent 2-3 
independent experiments. Error bars represent the mean ± SEM. Student unpaired t test was used. (ns, 
not significant, *p < 0.05, **p < 0.01, ***p < 0.001).  
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I next sought to determine if Nrp1–/– Treg-derived IFNγ from could drive Nrp1+/+ 
Treg fragility in vivo.  To address this, I used Foxp3–/– mice that lack Tregs and succumb to 
a scurfy-like phenotype if Tregs are not adoptively transferred within 48 hours of birth 34. 
Tregs of a single genotype or a 50:50 mixture of two different Treg genotypes were 
adoptively transferred into two-day-old Foxp3–/– mice.  At 4 weeks of age, mice were 
injected with B16 melanoma and tumor growth assessed over time (Fig. 12A). Mice 
were monitored after Treg injection and removed from study prior to B16 injection if any 
signs of autoimmunity were observed 34.  Tumor growth in Foxp3–/– mice that received 
either Nrp1+/+ Tregs, Nrp1–/– Tregs or a 50:50 mixture of Nrp1+/+ and Nrp1–/– Tregs 
phenocopied tumor growth in Foxp3Cre-YFP/Cre-YFP, Nrp1L/LFoxp3Cre-YFP/Cre-YFP and 
Nrp1L/LFoxp3Cre-YFP/DTR-GFP mice, respectively (Fig. 1E and 12B-D and Fig. 11E).  I then 
assessed the impact of Treg-derived IFNγ on tumor growth by transferring either [a] 
Nrp1+/+ Tregs that cannot respond to IFNγ with Nrp1–/– Tregs (50% Nrp1+/+Ifngr1–/– + 50% 
Nrp1–/–Ifngr1+/+), or [b] Nrp1–/– Tregs that cannot produce IFNγ with Nrp1+/+ Tregs (50% 
Nrp1+/+Ifng+/+ + 50% Nrp1–/–Ifng–/–).  Strikingly, tumor growth was completely restored 
with either combination (Fig. 12E-H), revealing a critical role for IFNγ produced by 
fragile Nrp1–/– Tregs in mediating Nrp1+/+ Treg dysfunction, and thereby facilitating anti-


















Figure 12: IFNγ uptake by Tregs is required for Treg fragility and tumor clearance. 
Tumor growth curves. (A-G) Foxp3–/– mice were injected with 106 Tregs on day 2 post-birth, and monitored 
for 28 days for the onset of any autoimmune symptoms [4 of 34 mice were removed from study], no more 
than 1 per experimental group.  B16.F10 was injected ID on day 28 and tumor size was measured every 
3 days. (H) Statistics of Foxp3–/– mice tumor growth.  Data represent 5-7 independent experiments with 5-
7 mice per experimental group. Error bars represent the mean ± SEM. 2 way ANOVA was used. (ns, not 




In summary, my data highlight seven key observations.  [i] A high proportion of human 
Tregs expressed NRP1 in two tumor types: melanoma and HNSCC.  It is also noteworthy 
that PBL Tregs from these cancer patients also possessed a clear population of NRP1+ 
Tregs in contrast to healthy donor PBL Tregs, which exhibited little to no NRP1 expression, 
suggesting that patient Tregs could be recirculating through the periphery. Interestingly, 
the percentage of intratumoral NRP1+ Tregs appeared to correlate with poor disease 
prognosis.  [ii] B16 tumors were rapidly cleared in mice harboring a 50:50 mixture of 
Nrp1-deficient and WT Tregs due to increased functional fragility and loss of suppressive 
activity of both Treg populations without loss of Foxp3 expression.  This was the result of 
Nrp1-deficient Treg fragility rather than the generation of Foxp3– ex-Tregs.  [iii] Treg fragility 
had a reciprocal impact on the transcriptomes of Nrp1-deficient and WT Tregs, 
highlighting the previously unappreciated fact that Tregs can impact other Treg 
populations directly as well as many other cell types. [iv] The induction of IFNγ pathway 
genes was a dominant feature of Treg fragility in tumors. Intratumoral Tregs were more 
susceptible to this functionally fragile phenotype due to the hypoxic tumor 
microenvironment, which led to increased Hif1α expression and IFNγ production 132.  
While it is possible that IFNγ derived from other sources could lead to Treg fragility, I 
have shown that hypoxia promoted IFNγ production and Treg fragility. [v] IFNγ, 
exogenously-provided (human or mouse) or intratumoral Nrp1–/– Treg-derived (mouse), 
was capable of driving the fragility of tumor-derived WT Tregs and loss of mouse and 
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human Treg suppressive activity in vitro.  This was a direct effect of IFNγ or Nrp1–/– Treg-
derived IFNγ as no other cells types were included in the in vitro experiments. Previous 
studies have suggested that IL-12 can impact Treg suppression and induce IFNγ 
expression 130, 131, 133, while others show that IFNγ can limit Treg expansion 134, 135, 136, 137. 
However, the direct effect of IFNγ on Treg function in vivo had surprisingly not been 
appreciated. While some studies have shown that IFNγ+ Tregs can maintain suppressive 
function, this seems to be largely disease specific and has not been carefully assessed 
in the context of the tumor microenvironment 138, 139. It is possible that the tumor 
microenvironment plays a critical role in driving IFNγ-mediated Treg fragility, as 
suggested by the role of Hif1α in this process. In addition, while I anticipate that IL-12 
may be playing a role in this process given that I see increased pSTAT4 expression, I 
have shown that IFNγ is capable of driving Treg fragility both in vitro and in vivo in tumor-
derived Tregs exposed to a hypoxic environment, suggesting that IL-12 may not be 
essential.  [vi] Intratumoral Treg fragility was mediated by IFNγ derived from Nrp1–/– Tregs 
that acted on WT intratumoral Tregs, thereby leading to their fragility and loss of 
suppressive activity.  This was supported by the fact that inclusion of WT Tregs that could 
not respond to IFNγ or Nrp1–/– Tregs that could not produce IFNγ restored Treg function, 
block anti-tumor immunity, and promote tumor growth.  While these data suggest that 
Nrp1–/– Treg-derived IFNγ is required, I do not yet know if it is sufficient.  These 
observations were consistent with a model in which fragile Nrp1–/– Tregs produce large 
amounts of IFNγ in the tumor microenvironment that directly promotes the fragility of 
intratumoral WT Tregs without loss of Foxp3 expression.  Importantly, this occurred 
without any detectable peripheral Treg fragility and without impacting their maintenance 
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of peripheral tolerance, suggesting that this was a proximally- and locally-driven event, 
likely induced by inflammation. While I only observed this in the context of the tumor 
microenvironment, it is possible that Treg fragility could indeed occur in other 
inflammatory settings where exposure to IFNγ is increased. I would argue that the 
mechanism of IFNγ-induced Treg fragility is mediated directly between Nrp1–/– and WT 
Tregs as either loss of IFNγ or IFNγR expression, respectively, impacts fragility. While it 
is possible that IFNγ derived from other cell populations, such as CD8+ T cells or NK 
cells, or the ensuing anti-tumor response and altered tumor microenvironment 
contributed to Treg fragility, it is noteworthy that the dominant IFNγ-producing cell type 
was Nrp1–/– Tregs and CD8+ T cell depletion did not impact the enhanced IFNγ 
production and loss of suppressive activity observed.   
A previous study had suggested that the absence of Nrp1 leads to reduced influx 
of Tregs into certain tumor types (Vegfa+/+ or Vegfa–/– fibrosarcomas and Ret melanoma 
models) 122.  However, I did not observe any defect in the migration of Nrp1-deficient 
Tregs even in the competitive environment of B16 tumors in heterozygous 
Nrp1L/LFoxp3Cre-YFP/DTR-GFP female mice.  These discrepancies could be due to the 
different tumor models analyzed.  Alternatively, their study primarily utilized 
Nrp1L/LCD4Cre mice in which Nrp1 would be removed in all T cells, which could have 
many direct and indirect effects on intratumoral Tregs 122.  Indeed, it has been previously 
shown that Nrp1 is expressed on a number of cell types, especially in the tumor 140 
(data not shown).  
The loss of Nrp1 not only results in Treg fragility but also results in substantial 
IFNγ expression, which in turn induces fragility in other Tregs regardless of their Nrp1 
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expression in a feed-forward manner; a process I refer to as “infectious fragility”. My 
data suggest that loss of Nrp1 stabilizes Hif1α expression, which then binds Ifng and 
upregulates expression. While our data highlight the role of IFNγ acting through 
paracrine signaling, it is possible that it also acts in an autocrine fashion on the Treg. As 
IFNγ production is a hallmark of a productive T cell-mediated immune response, my 
observations also raise the possibility that IFNγ-induced Treg fragility may be a 
physiologically important regulatory mechanism to locally limit Treg function and promote 
a productive immune response.  Given the profound consequences of Treg-derived IFNγ 
production, my data emphasize the importance of the Nrp1 pathway in limiting Treg 
fragility in the tumor microenvironment but also highlights that this pathway can be 
overcome when sufficient IFNγ is induced. I speculate that the IFNγ pathway may drive 
Treg fragility in certain inflammatory environments.   
As a high frequency of intratumoral Tregs in cancer patients is largely considered 
a negative prognostic factor 105, 141, 142, identifying approaches to selectively target 
intratumoral Tregs while maintaining peripheral tolerance is critical.  Although expression 
of NRP1 in peripheral, tissue-resident Tregs remains unclear, my findings highlight the 
surprisingly extensive and variable expression of NRP1 on human intratumoral Tregs 112, 
143, 144, 145. Importantly, given that my mouse model experiments suggest that NRP1 may 
not need to be targeted in all human intratumoral Tregs to derive a therapeutic effect, it is 
possible that targeting NRP1+ intratumoral Tregs with an NRP1 mAb may be therapeutic. 
As I show that the impact of the IFNγ pathway on human Tregs is conserved, it is 
possible that by blocking NRP1 on Tregs, one could induce functional fragility in 
surrounding Tregs to further enhance the therapeutic effect and overall outcome.  My 
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identification of IFNγ as the critical mediator of Treg fragility highlights the potential 
importance of this mechanism in promoting anti-tumor immunity and provides a pathway 
to develop immunotherapeutic approaches that could lead to tumor reduction while 
maintaining peripheral tolerance.  
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4.0   THE ROLE OF TREG FRAGILITY IMMUNOTHERAPEUTIC RESPONSE 
Portions of this chapter (4.3) are included within a manuscript published in Cell in 2017 
while other portions (4.4) are unpublished but are in preparation for submission. 
4.1 SUMMARY 
In chapter 3, I showed that Tregs can lose suppressive function, secrete IFNγ, but 
maintain Foxp3 expression, a term I refer to as ‘Treg fragility’. Indeed, Tregs treated with 
IFNγ were less suppressive; however, whether IFNγ-mediated Treg fragility was required 
for a productive anti-tumor immune response, especially in the context of 
immunotherapy, remained unclear. In this chapter, I show that IFNγ-induced Treg fragility 
is required for response to anti-PD1, and other immunotherapies are less effective in 
Ifngr1L/LFoxp3Cre-YFPmice. Taken together, these data suggest that cancer therapies 
promoting Treg fragility may be efficacious.  
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4.2 INTRODUCTION 
IFNγ+ Tregs have been observed previously in both human and mouse samples 44, 133, 146. 
IFNγ+ Tregs were previously describe in human glioblastoma 146, and were found to be 
less suppressive and PD1Hi. Interestingly, when patients were treated with anti-PD1, the 
percentage of IFNγ+ Tregs increased, suggesting that PD1 blockade could exert efficacy 
in part by skewing the Treg population. While it has been previously shown that Tregs 
could lose suppressive function and secrete IFNγ while maintaining Foxp3 expression 
(Treg fragility), the role of this in patient response to immunotherapy remains unclear. 
4.3 TREG FRAGILITY IS REQUIRED FOR EFFECTIVE RESPONSE TO ANTI-PD1 
While my previous data suggested a prominent role for IFN-γ in driving Treg fragility, the 
importance for this observation in the broader context of an immunotherapeutic 
response is unknown. I sought to address this question using mice that lack IFN-γR on 
Tregs (Ifngr1L/LFoxp3Cre-YFP) (Fig. 13A and B). Ifngr1L/LFoxp3Cre-YFP or Foxp3Cre-YFP mice 
were injected with 5x105 MC38 (an anti-PD1 sensitive tumor cell line) subcutaneously 
(SC) and then treated with either anti-PD1 or Armenian Hamster IgG control (200ug) on 
Days 6, 9 and 12 post-tumor injection. Strikingly, Ifngr1L/LFoxp3Cre-YFP mice were 
completely resistant to PD1 blockade in comparison to Foxp3Cre-YFP mice, as exhibited 
by tumor growth and survival (Fig. 13C and Fig. 14A). Consistent with the loss of IFN-
γR expression preventing the development of Treg fragility, no increase in percentage of 
IFNγ+ Tregs was observed in Ifngr1L/LFoxp3Cre-YFP mice in contrast to Foxp3Cre-YFP mice 
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following anti-PD1 treatment (Fig. 14B).  Taken together, these data suggest that IFN-γ-










Figure 13: Ifngr1L/LFoxp3Cre-YFP mice are non-responsive to PD1 blockade. 
Ifngr1L/LFoxp3Cre-YFP mouse analysis. (A) Lymphocytes were isolated from ndLN of Foxp3Cre-YFP or 
Ifngr1L/LFoxp3Cre-YFP mice and stained for IFNγR (n=2). (B) Tconv, Tregs, CD8s, or B cells were isolated from 
LN and spleen of Foxp3Cre-YFP or Ifngr1L/LFoxp3Cre-YFP mice, DNA was extracted for endpoint PCR testing 
for the presence or absence of the loxP sites or excision of loxP-targeted sequence (n=2). (C) Foxp3Cre-
YFP or Ifngr1L/LFoxp3Cre-YFP mice were injected with MC38 on day 0, sacrificed on day 13 (n=3-6). Data 








Figure 14: IFNγ-mediated Treg fragility is required for anti-PD1 response. 
(A-B) Tumor growth curve. Foxp3Cre-YFP and Ifngr1L/LFoxp3Cre-YFP mice were injected with MC38 SC on 
day 0 and treated with either anti-PD1 or isotype on days 6, 9, and 12 (200ug, 200ug, 200ug). (A) Tumor 
growth was measured with digital calipers every three days. Mice were removed from study when tumor 
growth reached a diameter of 2cm in any direction or when necrosis was observed, and survival plots 
were generated. (B) Flow cytometry analysis of Tregs. Lymphocytes were isolated from TIL on day 12 from 
Foxp3Cre-YFP and Ifngr1L/LFoxp3Cre-YFP mice and were stimulated and stained for IFNγ. Data represent 2 
independent experiments with 4-11 mice per experimental group.  2 way ANOVA (Fig. 14A), Kaplan-
Meier test (Fig. 14A), and Student unpaired t test (Fig. 14B) were used (**p < 0.01, ***p<0.001, ****p < 
0.0001). 
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4.4 TREG FRAGILITY WITHIN OTHER IMMUNOTHERAPIES 
In order to determine whether the contribution of fragile Tregs to immunotherapeutic 
response was limited to anti-PD1, I sought to determine whether this was a conserved 
event across tumor and treatment types as well as determine whether PD-1 blockade 
affected Treg function. I used three models to test this. First, I injected C57BL/6 mice 
with MC38 and treated with a combination of anti-PD1 and anti-LAG3. Similar to mice 
treated with anti-PD1 alone, Ifngr1L/LFoxp3Cre-YFP mice were less susceptible to 











Figure 15: IFNγ induced Treg fragility is required for response to PD1/LAG3 dual blockade. 
Tumor growth curve of Ifngr1L/LFoxp3Cre-YFP and Foxp3Cre-YFP mice that were injected with 5x106 MC38 
cells s.c. and treated with antiPD1 and antiLAG3 (200ug i.p. each) on days 6, 9, and 12. Tumors were 
measured every 3 days with electric calipers. Data represent 2 individual experiments. 
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To see if this effect would be maintained when other strategies were used, I treated B16 
melanoma-bearing mice with the “AIPV” regimen, defined by Darrell Irvine 147. Briefly, 
mice were given a high dose of B16 on day 0 (1x106 cells), and subsequently treated 
with a tumor specific antibody (anti-Trp1 “A”), mouse serum albumin fused IL-2 (“I”), 
anti-PD1 (“P”), and an amphiphile vaccine composed of peptide antigens and CpG DNA 
(“V”) weekly for three weeks starting when tumors are 40-60mm2, followed by “AI” 
treatment weekly for the remainder of the experiment. Ifngr1L/LFoxp3Cre-YFP mice were 
less susceptible to treatment compared to WT; however, the difference was not as great 









Figure 16: AIPV treatment efficacy is reduced upon deletion of Ifngr1 in Tregs. 
Tumor growth curve of Ifngr1L/LFoxp3Cre-YFP and Foxp3Cre-YFP mice that were injected with 1x106 B16 cells 
and treated with anti-Trp1 (100ug i.p.), MSA-IL-2 (30ug i.p.), anti-PD1 (200ug i.p.), and an amphiphile 
vaccine (1.24 nmol amph-CpG and 20ug amph-peptide s.c. at base of the tail) weekly for three weeks 
starting when tumors were 40-60mm2, continued with anti-Trp1 and MSA-IL2 treatment weekly for the 




Two potential reasons for this are that “AIPV” treatment targets a variety of both 
adaptive and innate immune cells, which could diminish the effects on tumor growth by 
Treg fragility or that other drivers of Treg fragility are required to see an effect on tumor 
growth. Whether “AIPV” treatment increases IFNγ secretion by Tregs or reduces Treg 
suppression remains unknown. Lastly, I used a model system where therapy targets the 
Treg compartment through the use of an agonist anti-GITR antibody. In this system, 
Ifngr1L/LFoxp3Cre-YFP mice were again less susceptible to treatment compared to WT; 
however, how this treatment affects the IFNγR– Tregs in this system remains unknown 
(Fig. 17). Use of anti-GITR has been previously shown to reduce the Treg frequency 











Figure 17: Treatments targeting Tregs require fragility for efficacy. 
Tumor growth curves of Ifngr1L/LFoxp3Cre-YFP and Foxp3Cre-YFP mice that were injected with 50,000 B16 
cells and treated with anti-GITR (1mg, i.p.) on day 4. Tumors were measured every 3 days with electric 
calipers. Data represent 2 independent experiments. 
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To determine if immunotherapeutic treatment affected Treg function in the TME, I 
performed a microsuppression assay with WT or Ifngr1–/– Tregs isolated from ndLN and 
TIL of MC38 tumor-bearing mice treated with anti-PD1. Although subtle, I did observe a 
trend showing that Ifngr1–/– Tregs remained more suppressive after PD1 blockade 
compared to WT Tregs from the TIL, while no differences were observed in the ndLN 
(Fig. 18). However, whether this difference (a) is a direct or indirect effect on Tregs, and 
(b) is exacerbated at later time points or in other immunotherapeutic settings remains to 
be determined. It would also be of interest to isolate Tregs from responders and non-









Figure 18: Ifngr1–/– Tregs maintain suppression after PD1 blockade. 
Microsuppression assay after Ifngr1L/LFoxp3Cre-YFP and Foxp3Cre-YFP mice were treated with anti-PD1 on 
D6, 9, 12. Tregs were pooled from 3 mice with 5-6 mice per group per experiment. Proliferation was 






I have shown that IFNγR expression on intratumoral Tregs was required for an effective 
response to PD1 blockade. Strikingly, Ifngr1L/LFoxp3Cre-YFP mice which like the IFNγ 
receptor on Tregs were completely resistant to anti-PD1 immunotherapy. Whereas WT 
Tregs showed a significant increase in IFNγ expression after PD1 blockade, Ifngr1–/– Tregs 
showed no increase in IFNγ, suggesting that IFNγ-driven Treg fragility may need to be 
induced for an effective immunotherapeutic response.  
Whether Treg fragility is a feature of certain diseases and the extent to which this can be 
prevented or utilized therapeutically remains largely unknown and highly controversial 
64, 69, 71, 73. Indeed, my data show that the IFNγ response induced by PD1 blockade 
appears to be sufficient to drive intratumoral Treg fragility despite expression of Nrp1.  
Loss of IFNγR expression on Tregs renders mice completely resistant to anti-PD1 
immunotherapy and are partially resistant to other immunotherapies, including AIPV, 
anti-GITR, and anti-PD1/LAG3.  This raises the provocative possibility that an essential 
component of effective immunotherapy (antibody or vaccine mediated) is to induce 
sufficient IFNγ in the tumor microenvironment to drive Treg fragility.  However, the impact 
of Treg fragility and IFNγ expression by intratumoral Tregs on tumor growth and 
responsiveness to immunotherapy in murine and human tumors needs to be 
investigated further.  Some underlying questions remain from these experiments: First, 
is Foxp3 expression reduced in WT or Ifngr1–/– Tregs after treatment? Second, is 
suppression differentially affected by various immunotherapies treatment in these two 
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Treg populations? While Ifngr1L/LFoxp3Cre-YFP mice are less responsive to all therapies in 
this chapter, the extent of responsiveness varies considerably, suggesting that different 
therapies have varying effects on Treg fragility. This could occur due to the cell targeted 
by the therapy. For example, while anti-GITR targets Tregs directly, “AIPV” treatment 
targets a number of cell populations, both adaptive and innate. Thirdly, are there are 
other drivers of Treg fragility? Indeed, it is possible that other cytokines may induce Treg 
fragility in conjunction with IFNγ, as the TME has many secreted molecules that are 





5.0  TREGS MAINTAIN METABOLIC PLASTICITY AND FUNCTION THROUGH THE 
NRP1:HIF1Α AXIS IN THE TUMOR MICROENVIRONMENT 
This project is part of a collaboration between myself and the Delgoffe lab, with 
contributions from Ashley Menk and Greg Delgoffe. It has been compiled into a 
manuscript for submission in 2018. 
5.1 SUMMARY 
Regulatory T cells are required to maintain immune homeostasis and prevent 
autoimmunity; however, they act as a barrier to anti-tumor immunity and are considered 
a possible mechanism of resistance to immunotherapy. Therefore, it would be 
advantageous to uncover tumor Treg specific targets. Neuropilin-1 (Nrp1) is required to 
maintain intratumoral Treg stability but has no effect on peripheral Tregs. The tumor 
microenvironment is unique and is thought to support Tregs metabolically while starving 
other effector T cell subsets through ravenous glucose uptake and immunosuppressive 
metabolite secretion. I show that Nrp1–/– Tregs reside in areas of lower hypoxia, but 
maintain Hif1α. As a result of this sustained expression, Nrp1–/– Tregs are reliant on 
glycolysis and are less suppressive in low glucose environments both in vivo and in 
vitro. As a result, CD8 T cells from Nrp1L/LFoxp3Cre-YFP mice are less metabolically 
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exhausted and contribute to reduced tumor growth or tumor clearance. Lastly, loss of 
both Nrp1 and Hif1α on Tregs leads to partial rescue of tumor growth. Taken together, 
my data indicate that Nrp1 maintains metabolic fitness and suppressive capacity in 
tumor-Tregs through restraint of Hifα. 
5.2 INTRODUCTION 
The tumor microenvironment is unique and supports immunosuppressive cells such as 
Tregs through both enhanced recruitment via chemokines and through altered 
metabolism. Cancer cells perform aerobic glycolysis, also known as the “Warburg 
effect”, where they perform glycolysis even in the presence of oxygen, which is thought 
to provide them with the constant energy required for their rapid proliferation 148, 149. 
Because of this, cancer cells act as a glucose “sink”, depriving surrounding glucose-
dependent cells, such as Teff cells, of the nutrients they need to thrive in this 
environment 150, 151. In addition this, the environment is hypoxic 152, lacks metabolites 
like glutamine 153, and has a surplus of immunosuppressive metabolites such as lactate 
154, 155. 
Tregs are distinct metabolically compared to other T cell subsets, which allows them to 
survive and proliferate better within the tumor microenvironment compared to other T 
cell subsets. Unlike other T cells, Tregs primarily utilize oxidative phosphorylation 
(OXPHOS) rather than glycolysis to fuel their energetic needs 156, 157. Treg metabolism is 
directly controlled by Foxp3-mediated suppression of Myc and the glycolysis pathway, 
thereby developing a metabolic advantage in areas of low glucose. In addition, Tregs 
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preferentially produce pyruvate from L-lactate rather than producing their own lactate, 
suggesting they may survive better in areas of high lactate, such as the tumor 
microenvironment. Indeed, the addition of L-lactate to Treg cultures had no effect on their 
proliferation or function 158. However, the majority of these studies were done in vitro 
with induced Tregs (iTregs), so whether this occurs in the tumor remains unclear. I have 
previously shown that Nrp1 contributes to Treg stability within the tumor 
microenvironment and in its absence, Tregs express higher levels of hypoxia inducible 
factor 1α (Hif1α), produce IFNγ, and lose suppressive function through downregulation 
of Hif1α and prevention of IFNγ secretion 44. While Hif1α can be upregulated as a 
consequence of hypoxia, it can also be upregulated in normoxic conditions as a result of 
Akt activation 128, 159; indeed, Nrp1-/- Tregs have increased Akt activity within the TME. 
However, many questions remain including: a) does Nrp1 restrain Hif1α in the tumor 
microenvironment? b) Does the downregulation of Hif1α affect Treg metabolism? and c) 
Is loss of function in Nrp1–/– Tregs within the tumor microenvironment dependent on 
Hif1α?  
5.3 RESULTS 
5.3.1 Nrp1 restrains Hif1α in the TME 
Previous studies have highlighted a role for Nrp1 in maintained Treg stability within the 
tumor microenvironment, and in its absence, tumor-derived Tregs secrete IFNγ and 
contribute to anti-tumor immunity 43, 44. In addition, Nrp1–/– Tregs expressed significantly 
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more Hif1α, suggesting that IFNγ secretion was controlled through this pathway. I 
hypothesize that in the absence of Nrp1, Akt activity is increased, leading to higher 
Hif1α expression and subsequent IFNγ secretion 128, 129. As Hif1α expression can also 
be increased as a result of hypoxia, I first asked whether Nrp1–/– were located in areas 
of higher hypoxia within the tumor microenvironment. Surprisingly, Nrp1–/– were less 
hypoxic, as visualized by pimonidazole:Hypoxiprobe staining (Fig. 19 A, B), suggesting 
that Hif1α expression was being driven by an alternate mechanism. Interestingly, I 
found that Hif1α expression was significantly reduced in tumor-derived Tregs in WT mice 
compared to Nrp1–/– Tregs that either maintained or showed an increase in expression 
within the tumor (Fig. 19 C, D), suggesting that Nrp1 may restrain Hif1α in Tregs within 
the tumor microenvironment, and that in its absence, higher Hif1α leads to increased 



























Figure 19: Nrp1–/– Tregs are less hypoxic but maintain Hif1α expression in the TME. 
(A) Hypoxia staining. Tumors were harvested from Foxp3Cre-YFP and Nrp1L/LFoxp3Cre-YFP mice on day 12, 
sectioned, and stained for Foxp3, Hypoxia via pimonidazole:Hypoxiprobe, and DAPI. (B-D) Flow 
cytograms of hypoxia and Hif1α. Lymphocytes were harvested from ndLN, dLN, and TIL of Foxp3Cre-YFP 




5.3.2 Nrp1–/– Tregs are glycolytic 
Given that Hif1α has been previously shown to induce glycolysis through pyruvate 
dehydrogenase (PDK) activation 160, 161, I sought to determine whether the increase in 
Hif1α in Nrp1–/– Tregs in the tumor made them more glycolytic. While Teff cells are largely 
dependent on glycolysis, Tregs rely primarily on fatty acid oxidation and oxidative 
phosphorylation. Tumor cells are thought to shift the tumor to an immunosuppressive 
microenvironment by taking up a majority of the glucose available and producing 
immunosuppressive metabolites such as lactate, thereby ‘starving’ Teff and ‘feeding’ 
Tregs respectively 158, 162. Therefore, I hypothesized that Nrp1–/– Tregs are reliant on 
glycolysis as a result of Hif1α and are less suppressive in the tumor microenvironment 
due to the lack of available glucose. Indeed, Nrp1–/– Tregs upregulated components of 
the glycolysis pathway (Fig. 20 A) and were less oxidative, as shown by a decrease in 
OCR, increase in ECAR (Fig. 20 B, C). In addition, Nrp1–/– appeared more metabolically 
exhausted as indicated by spare respiratory capacity (SRC) (Fig. 20 D) and had less 
ATP reserves (Fig. 20 E). To determine whether Nrp1–/– Tregs were reliant on glucose 
and therefore were less suppressive in its absence, I stimulated WT and Nrp1–/– Tregs in 
either high (25mM) or low (~5mM) glucose media for 3 days prior to re-isolating them for 
a suppression assay. Strikingly, Nrp1–/– Tregs were significantly less suppressive after 
culture in low glucose, while WT Tregs maintained function (Fig. 20 F) suggesting 
functional reliance on glucose. While 5mM glucose is lower than standard culture 
media, it is still considerably higher than levels found in the TME163, so studies looking 



















Figure 20: Nrp1–/– Tregs are glycolytic. 
(A) RNASeq analysis. Tregs were purified based on CD4+, and GFP or YFP expression from Foxp3Cre-
YFP/Cre-YFP, and Nrp1L/LFoxp3Cre-YFP/Cre-YFP mice on D12, cDNA and libraries were generated using the 
Clontech SmartER Ultra-Low and Illumina Nextera XT Library Prep kits. Samples were normalized to 2nM 
and sequenced on a NextSeq500. A number of genes associated with the glycolysis pathway were 
upregulated in the Nrp1–/– samples. Data represent 5 independent experiments with 3-5 mice pooled per 
experiment. (B-E) Metabolic analysis. Lymphocytes were harvested from ndLN and TIL of Foxp3Cre-YFP 
and Nrp1L/LFoxp3Cre-YFP mice on day 12 and used in a (B-D) Seahorse assay or an ATP determination 
assay (E). (F) Microsuppression assay. Lymphocytes were isolated as above and cultured in stimulating 
conditions in high or low glucose media for 3 days prior to being used a microsuppression assay. *p<0.05, 
**p<0.01, ***p<0.001. 
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Interestingly, Nrp1–/– Tregs did not show a significant reduction in mitochondrial mass or 
function (Fig. 21 A, B); however, both WT and Nrp1–/– Tregs showed a reduction in both 
mass and function over tumor progression, and this correlated with higher PD-1 















Figure 21: Tregs lose mitochondria and upregulate PD-1 in the tumor microenvironment. 
Flow cytograms of mitochondrial mass and function in correlation with PD-1. (A-C)  Lymphocytes were 
harvested from ndLN, dLN, and TIL of Foxp3Cre-YFP and Nrp1L/LFoxp3Cre-YFP mice on day 12 and stained 






5.3.3 Nrp1 supports OXPHOS through PGC1α expression 
As Nrp1–/– Tregs were more glycolytic and less oxidative compared to WT Tregs, I asked 
whether there were also alterations within the OXPHOS pathway. PPAR-gamma 
coactivator 1 α (PGC1α) supports mitochondrial biogenesis and OXPHOS 164, and has 
been previously shown to be required for maintained Teff function in the tumor 
microenvironment 165.  Interestingly, I found that PGC1α was downregulated in Nrp1–/– 
Tregs in comparison to WT Tregs within the ndLN but was similarly downregulated in both 
Treg populations within the tumor microenvironment (Fig. 22 A-C), suggesting that there 
are Nrp1-driven changes in both the glycolytic and OXPHOS pathways that lead to 
altered Treg metabolism within the tumor microenvironment. However, in order to 
determine the direct or indirect role of Nrp1 on PGC1α levels within the TME, one would 
need to perform genetic deletion experiments, and ideally, utilize a system where one 






Figure 22: Nrp1 restrains PGC1α. 
PGC1α expression levels by flow cytometry and qPCR. (A-B)  Lymphocytes were harvested from ndLN, 
dLN, and TIL of Foxp3Cre-YFP and Nrp1L/LFoxp3Cre-YFP mice on day 12 and stained. (C) Lymphocytes were 
harvested from ndLN, dLN, and TIL of Foxp3Cre-YFP and Nrp1L/LFoxp3Cre-YFP mice on day 12, RNA was 
isolated, and qPCR was performed. **p<0.01, ****p<0.0001. 
 86 
5.3.4 CD8+ T cells are more oxidative and less exhausted from Nrp1L/LFoxp3Cre-
YFP mice 
Given that PGC1α has been shown to be required to prevent exhaustion and maintain 
function of CD8+ Teff in the tumor microenvironment and that Nrp1L/LFoxp3Cre-YFP mice 
have substantially reduced tumor growth that is dependent on CD8+ T cells 44, 165, I 
sought to determine whether the loss of Nrp1 on Tregs and subsequent metabolic 
deficiency affected intratumoral CD8+ T cell metabolic exhaustion. CD8+ T cells isolated 
from Nrp1L/LFoxp3Cre-YFP mice (herein referred to as CD8Nrp1) maintained mitochondrial 
mass and function within the tumor compared to those from Foxp3Cre-YFP mice (herein 
referred to as CD8WT) (Fig. 23A). In addition, CD8Nrp1 T cells were less metabolically 










Figure 23: CD8+ T cells are less metabolically exhausted in Nrp1L/LFoxp3Cre-YFP mice. 
(A-B) Lymphocytes were harvested from ndLN and TIL of Foxp3Cre-YFP and Nrp1L/LFoxp3Cre-YFP mice on 
day 12 and (A) stained or (B) used in a Seahorse assay. **p<0.01. 
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5.3.5 Hif1α restraint is required for Treg function in the TME 
As Hif1α was decreased in WT Tregs but not Nrp1–/– Tregs within the TME, I reasoned that 
part of the reduction in tumor growth in Nrp1L/LFoxp3Cre-YFP mice may indeed due to 
sustained Hif1α expression and subsequent IFNγ production by Tregs. In order to test 
this possibility, I injected Nrp1L/LHif1aL/LFoxp3Cre-YFP mice with B16 to see if tumor 
growth was affected. Nrp1L/LHif1aL/LFoxp3Cre-YFP mice showed partially restored tumor 
growth compared to Nrp1L/LFoxp3Cre-YFP mice (p<0.05), suggesting that Nrp1 sustains 
Treg function and stability in part by restraining Hif1α. However, whether (a) this effect is 
conserved across tumor types and (b) Nrp1–/–Hif1a–/– Tregs are less fragile compared to 











Figure 24: Loss of Nrp1 and Hif1α on Tregs partially rescues tumor growth. 
Tumor growth curve. Foxp3Cre-YFP, Nrp1L/LFoxp3Cre-YFP, Hif1aL/LFoxp3Cre-YFP, and Nrp1L/LHif1aL/LFoxp3Cre-
YFP mice were injected with B16 i.d. on day 0 and tumor growth was measured with digital calipers every 
three days. Mice were removed from study when tumor growth reached a diameter of 2cm in any 
direction or when necrosis was observed. n=4-10. Two way ANOVA was used. 
 88 
5.4 DISCUSSION 
In summary, my data show the following 5 observations: [i] Nrp1 restrains Hif1α in the 
tumor microenvironment. It is possible that this occurs to condition Tregs to better survive 
in a hypoxic environment as WT Tregs are more hypoxic than Nrp1–/– Tregs. [ii] Nrp1–/– 
Tregs are glycolytic unlike WT Tregs that primarily utilize OXPHOS. In addition, Nrp1–/– 
Tregs are dependent on glycolysis for function as they are no longer suppressive after 
culture in low glucose media while WT Tregs are not affected. [iii] Nrp1 directs Treg 
OXPHOS through upregulation of PGC1α. Indeed, PGC1α expression is decreased in 
Nrp1–/– Tregs in the ndLN. However, PGC1α levels are similarly low in the TME in both 
WT and Nrp1–/– Tregs, suggesting that there could be unknown environmental effects 
that drive down expression within the TME. [iv] CD8+ T cells are less metabolically 
exhausted in Nrp1L/LFoxp3Cre-YFP mice as indicated by maintained mitochondrial mass 
and function and elevated basal oxidative phosphorylation. [v] Nrp1–/– Tregs contribute to 
anti-tumor immunity in part by increased Hif1α expression. Surprisingly, loss of both 
Nrp1 and Hif1α on Tregs led to an increase in tumor growth compared to loss of Nrp1 
alone. This suggests that Hif1α restraint by Nrp1 on Tregs is required for maximal 
suppressive function and support of tumor growth; however, more studies are required 
to determine whether this is sufficient. Indeed, it is possible that other environmental 
changes are contributing to tumor growth in this system.  
Previous studies have suggested that Hif1α binds to Foxp3 and acts as a switch 
between TH17 and Treg development 128; however, its role in Treg function in the TME 
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remain unclear. Given that Nrp1 limits Akt activity, I speculate that Nrp1 restrains Hifα 
expression and sustains Treg function and oxidative metabolism. In the absence of Nrp1 
on Tregs, Hif1α expression is maintained in the TME, leading to increased IFNγ secretion 
and glucose dependency. It is possible that current immunotherapy efficacy could be 
improved by targeting Treg metabolism, specifically limiting them to glycolysis either 
indirectly through Nrp1 blockade or directly through inhibition of oxidative 
phosphorylation. However, many questions remain: (1) does Nrp1 directly support 
OXPHOS within the TME? (2) What factors within in the TME drive down PGC1α in 
Tregs? (3) Are Nrp1–/–Hif1a–/– Tregs less fragile than Nrp1–/– as determined by Treg IFNγ 
production and reduced suppression? (4) Would Nrp1L/LHif1aL/LIfngr1L/LFoxp3Cre-YFP 
mice harbor stable Tregs and therefore be completely resistant to immunotherapy? While 
subsequent studies are required, these data highlight the possibility that targeting Treg 




6.0  DISCUSSION 
Parts of this discussion were derived from a review I have compiled and submitted to 
Cancer Immunology Research. 
6.1 INTRODUCTION 
Tregs function as the master regulators of the immune system, maintaining 
homeostasis and preventing autoimmunity; however, they also support tumor growth 
through the suppression of the anti-tumor immune response.  
The tumor microenvironment is unique in that it is nutrient-poor, hypoxic, and 
acidic, making it a taxing environment for Teff that are primarily glycolytic. In contrast to 
this, Tregs rely on oxidative phosphorylation and are thought to have an proliferative and 
functional advantage within hypoxic, acidic environments 155.  
Increased Tregs have been observed in a variety of cancer patient peripheral 
blood and tumors, including non-small cell lung cancer, late stage ovarian cancer, 
breast cancer, and pancreatic cancer 166, 167. Many cancer types show a positive 
correlation between higher Treg percentages and poor prognosis in patients. Tregs 
percentages in the tumor mass increase with severity of stage in ovarian carcinoma 
patients 37. In addition, higher Treg percentages correlate with poorer disease-free 
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survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma, and 
classical Hodgkin’s lymphoma 38. As a result, Tregs have been targeted in the clinic, 
albeit with limited success.  Depletion strategies targeting the IL-2 pathway through use 
of antibodies or other small molecules led to off target effects such as depletion of 
effector T cells or loss of DC-mediated T cell activation, in addition to incomplete or 
transient depletion of Tregs 40, 41.  
CTLA-4 blockade has been identified as a potential Treg target due to high 
surface expression. Previous studies have shown that CTLA4 antibodies that had FcγR 
ADCC activity reduced Tregs in the TME, and that there was a positive correlation 
between reduced Tregs and CTLA-4 blockade response in bladder cancer patients 168. It 
was initially thought that CTLA-4 blockade worked on Tregs through either depletion or by 
reducing suppression 169; however, effects on both Teff and Treg compartments were 
required for full anti-tumor function 170. Indeed, anti-tumor effects were thought to be 
due to enhanced CD8+ T cell numbers rather than a decrease in Tregs within the tumor. 
Interestingly, blockade led to increased Tregs in the periphery; however, this also led to 
fewer Tregs in the tumor by both lack of accumulation and partial depletion due to higher 
CTLA-4 expression on intratumoral Tregs and the presence of FcγR-expressing 
macrophages.  Subsequent studies suggested that CTLA-4 blockade led to increased 
Teff in both the tumor and periphery 171.  
Anti-CCR4 antibody (mogamulizumab; defucosylated to enhance ADCC) is in 
clinical trials currently and targets Tregs through the CCL22:CCR4 mediated recruitment 
to the tumor and has shown some clinical efficacy 172. While encouraging, these 
strategies still show limited efficacy, thereby further highlighting the need to identify new 
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avenues with which to target Treg function, potentially through destabilization of Tregs or 
by driving Treg fragility specifically within the TME. 
Treg stability is defined as sustained Foxp3 expression, hypomethylation at the 
CNS2 locus, and maintained suppressive function; however, the prevalence and impact 
of Treg instability remains controversial 45, 64, 71, 72, 73. In contrast to Treg instability, Treg 
fragility has recently been defined as retention of Foxp3 expression with loss of 
suppressive function 44. Fragile Tregs produce IFNγ, and upregulate the IFNγ receptor as 
well the transcription factor, Tbet. In addition, they have reduced expression of 
suppressive molecules, such as CD73 and IL-10 and are functionally less 
suppressive44.  
In this chapter, I will address the following questions: (1) How is Treg stability 
maintained? (2) How is Treg fragility induced? (3) Is responsiveness to immunotherapy 
dependent on Treg fragility? 
6.1.1 Building up: how is Treg stability maintained? 
Treg stability has been discussed across many disease types in the past decade. 
Treg instability was initially defined as loss of Foxp3 expression in cells and subsequent 
loss of suppressive function. This is thought to be in part due to lack of demethylation or 
remethylation at certain sites within the Foxp3 locus 123. Demethylation in this locus was 
first described in 2007 when a region in the 5’ UTR of the Foxp3 locus containing a 
number of conserved demethylated CpG motifs, was identified (known as the 
TSDR/CNS2) 45. The demethylation pattern is observed in both thymic and mature 
peripheral Tregs in mice and peripheral blood of humans. In contrast, the CNS2 is largely 
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methylated in effector CD4+ T cells. Hypomethylation of the Foxp3 locus is required for 
Treg stability, but occurs independently of Foxp3 upregulation. Rather, hypomethylation 
is required for Foxp3 upregulation, and thus suppressive function and cell stability 48. 
Interestingly, it has been shown that TGFβ-induced Tregs (iTregs) display a somewhat 
hypermethylated Foxp3 locus 48; however, whether Foxp3+ Tregs with a methylated 
Foxp3 locus exist in vivo in sites of disease remains unclear. Indeed, IL-6 has been 
shown to lead to the remethylation of the CNS2 in vitro in a STAT3-dependent manner 
and also leads to reduced susceptibility of Tconv cells to Treg suppression 173. The 
possibility that there are other factors that lead to the remethylation of the locus in the 
TME warrants further investigation. 
In addition to epigenetic alterations of the Foxp3 locus, loss of Foxp3 expression 
is a hallmark of unstable Tregs. There are a number of factors involved in maintaining 
Foxp3 expression, including IL-2/STAT5 and Foxo1/3a. STAT5 binds to the Foxp3 locus 
and in its absence Treg development is reduced 77, while Foxo1 and Foxo3a translocate 
to the nucleus of Tregs and prevent effector functions 80. Induction of Foxp3 and 
subsequent Treg development can also be prevented by persistent TCR stimulation 
leading to constitutive activation of the PI3K/Akt/mTOR pathway 174, or in the absence 
of the microRNA processing enzyme, Dicer 175. 
Loss of Foxp3 expression has also been reported in certain disease settings 
such as lymphopenia and autoimmune diabetes 71. In these systems, fate-mapping 
mice were used to trace all cells that currently or previously expressed Foxp3, 
regardless of subsequent downregulation. In both cases, ex-Foxp3+ cells, or ‘exTregs’ 
upregulated IL7R, secreted IFNγ and IL17, took on a pathogenic role and worsened 
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disease 73. Other groups have reported that Foxp3 expression is stable and that 
previously identified exTregs were likely T cells that transiently upregulated Foxp3 during 
differentiation or activation 64, 74. Indeed, very few exTregs have been observed in mouse 
models of cancer 44, suggesting Foxp3 is largely stable in these models. Other studies 
have highlighted a role for Helios in maintaining Foxp3 expression and showed that in 
its absence, Foxp3 was reduced and Helios-deficient Tregs secreted IFNγ in the TME 176, 
177. However, whether unstable Tregs exist in patients is unknown and remains difficult to 
assess without cell lineage tracing capabilities.  
6.1.2 Breaking down: how is Treg fragility induced? 
Multiple factors have been reported previously to be important for preventing Treg 
fragility, including Nrp1, Foxo1 and Eos 43, 44 While Nrp1 can be expressed on a number 
of cell types, it is highly upregulated on Tregs and supports Treg function through binding 
of Semaphorin-4a (Sema4a). Upon Sema4a:Nrp1 ligation, PTEN is recruited to the 
immunological synapse and limits Akt activity, thus increasing translocation of Foxo1/3a 
to the nucleus. Given that Foxo1 represses Tbx21, it is possible that the lack of Nrp1 
and prevention of Foxo translocation leads to higher Tbx21 (Tbet) and subsequent IFNγ 
secretion 81, 82, 178. In the absence of Nrp1 signaling, either through Nrp1 blockade or 
genetic deletion (using Nrp1L/LFoxp3Cre-YFP mice), intratumoral Tregs show reduced cell 
survival, reduced expression of suppressive markers (such as CD73, IL-10 and IL35), 
and significantly impaired suppressive function.  Surprisingly this did not result in loss of 
Foxp3 expression. As a result, Nrp1L/LFoxp3Cre-YFP mice cleared tumors similarly to mice 
lacking Tregs; however, the mice displayed no signs of autoimmunity. Nrp1+ Tregs are also 
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increased in metastatic melanoma and head and neck squamous cell carcinoma 
patients compared to healthy donors 44. Furthermore, patients with a larger population 
of Nrp1+ Tregs correlated with reduced disease-free survival in comparison to those with 
a smaller population. It was later shown that Nrp1– Tregs produced IFNγ and were less 
suppressive than WT Tregs, but maintained Foxp3 expression. Secretion of IFNγ only 
occurred within the tumor microenvironment, likely as a result of sustained or increased 
Hif1a expression due to hypoxia and heightened Akt activity 43, 44, 128, 129. Indeed, it is 
possible that the unique environment within tumors (hypoxic, acidic, nutrient poor) 
contributes to Treg fragility and may underlie the preferential restriction of fragility to the 
tumor microenvironment. 
Previous reports have shown that while Foxo1 is key for Foxp3 upregulation 
during Treg development, the loss or mutation of Foxo1 from mature Tregs leads to a 
fragile phenotype rather than an unstable one. Specifically, Foxo1-deficient Tregs are 
less suppressive and secrete IFNγ; however, Foxp3 expression is maintained and in 
fact, the percentage of Tregs increases in vivo. Furthermore, Foxo1 deletion in Tregs leads 
to a lethal inflammatory phenotype that is dependent on IFNγ 81.  However, unlike the 
phenotype observed in the absence of Nrp1, wherein fragility appears to be restricted to 
the tumor microenvironment 43, 44 the loss of Foxo results in a fragile phenotype that is 
systemic, which leads to the inflammatory phenotype.  Similarly, Eos is highly 
upregulated in Tregs, and when removed, Treg suppression is reduced, IFNγ and IL-2 
are upregulated, but Foxp3 expression remains unchanged 84. Interestingly, it has been 
reported that when LAG3 is deleted on Tregs, Eos is increased and leads to better 
suppressive function in an autoimmune diabetes setting 179. Indeed, it is possible that 
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LAG3 limits Eos expression in Tregs, thereby promoting fragility; however, further studies 
are required.  
6.1.3 Is response to immunotherapy dependent on Treg fragility?  
Intratumoral Tregs display a distinct profile, suggesting that there may be specific 
markers that one could target within the TME that might lead to Treg instability 
(dysfunction and loss of Foxp3 expression) or Treg fragility (dysfunction while 
maintaining Foxp3 expression). However, whether this (a) is observed in cancer patient 
intratumoral Tregs and (b) predicts patient responsiveness, remains unknown. I 
hypothesize that Tregs within the TME upregulate stabilizing molecules, such as NRP1, 
and that patients who respond to immunotherapy show a more fragile intratumoral Treg 
phenotype. 
Treg fragility appears to be required for response to anti-PD1 in murine tumor 
models. In an adenocarcinoma mouse model (MC38) that is sensitive to PD-1 blockade, 
treatment of WT mice with anti-PD1 led to the upregulation of IFNγ+ Tregs, consistent 
with an increased fragile phenotype. Strikingly, when Tregs were insensitive to IFNγ 
(through the use of an Ifngr1L/LFoxp3Cre-YFP mouse), mice were completely resistant to 
PD-1 blockade in comparison to ~40% response in WT mice 44, suggesting a role of Treg 
fragility in responsiveness to immunotherapy. Similarly, reduction of tumor burden 
through the use of a GITR agonist antibody (DTA-1) is due to an increase in IFNγ+ Tregs 
and reduction in Helios expression 176, 180. As mentioned, CD8:Treg ratios have been 
shown to be indicative of patient response to therapy; however, the idea that Treg fragility 
 97 
is the key component to determining response to immunotherapy was previously 
unappreciated.  
Similarly, previous studies have identified IFNγ+ Tregs in human samples in 
autoimmune diseases, such as multiple sclerosis and type 1 diabetes, where these cells 
have reduced suppression and altered methylation while maintaining Foxp3 expression, 
suggesting a fragile phenotype 48, 133, 181.  In addition, patients with malignant glioma 
(GBM) exhibit a higher percentage of circulating PD-1Hi Tregs that are less suppressive 
and also express IFNγ. PD-1Hi Tregs bear a distinct transcriptional profile, are 
phenotypically exhausted as defined by upregulation of LAG3 and Tim3, and show a 
minor reduction in CNS2 demethylation. Interestingly, when GBM patients were treated 
with anti-PD1 (Nivolumab), the exhausted PD-1+ IFNγ+ Treg population increased 146. 
This population has been observed in other tumor types, such as late advanced rectal 
cancer (LARC), where it correlated with poorer patient response 36.These data suggest 
that PD-1 blockade as well as other immunotherapies may act in part through inducing 
a fragile Treg phenotype in patients.  Whether this is a direct effect of anti-PD1 on Tregs or 
and indirect effect of increased IFNγ in the TME acting on Tregs to drive fragility remains 
to be determined.  
Given that the impact of Treg fragility in immunotherapy has not been fully 
elucidated in clinic, assessing the extent to which patient Tregs develop a fragile 
phenotype following immunotherapy could aid in both prediction of patient susceptibility 
to anti-PD1 as well as providing a rationale for patient responsiveness to 
immunotherapy. Sensitizing Tregs to become fragile may be an effective strategy to 
utilize alongside PD-1 blockade. While PD-1 blockade has been shown to upregulate 
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IFNγ in CD8+ T cells, whether this directly affects Tregs remains unclear in the clinic. 
However, IFNγ-sensitive Tregs have been observed in patient samples, and were found 
to be less suppressive following IFNγ treatment 44. While PD-1 blockade has been the 
primary focus thus far, it is certainly possible that Treg fragility plays a key role in 
responsiveness to other immunotherapies currently in the clinic or perhaps the efficacy 
or any immunotherapy. One possibility would be to target a known driver of Treg fragility 
prevention, such as Nrp1. I would argue that inducing Treg fragility may be a preferred 
therapeutic strategy compared to Treg depletion or destabilizing Tregs because the effect 
on Tregs seems to be restricted to the TME, thereby preventing autoimmune effects. 
Identifying a way to target Treg fragility while leaving Treg stability intact may be 
critical, given the previously identified pathogenic nature of unstable Tregs or exTregs in 
various diseases 71, 72, 73. It is possible that local Treg destabilization strategies may be 
efficacious; however, the potential systemic autoimmune effects of this are unknown. 
Furthermore, distinguishing between these two Treg subsets can be challenging—while 
there are some clear markers of fragile Tregs, including Nrp1, PD-1 and IFNγR1, specific 
markers do not exist for unstable Tregs, that are often indistinguishable from Th-like cells. 
Furthermore, there may be more unappreciated markers of Treg fragility. In addition, 
tracking the presence of exTregs in patient samples is not feasible currently.  
While I feel that targeting molecules that prevent Treg fragility in the clinic 
represents the clearest step forward, many interrelated questions remain: (1) What are 
the markers of unstable or exTregs in patients? (2) Are there other drivers of Treg fragility? 
While IFNγ has been shown to drive Treg fragility, it is possible that other cytokines or 
soluble factors could lead to a similar phenotype. (3) Do fragile Tregs display 
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hypermethylation at the Foxp3 CNS2 locus, and does this lead to reduced suppressive 
function? While previous studies have suggested that hypomethylation is required for 
sustained Foxp3 expression, our direct ex vivo methylation analysis (Appendix B) 
suggest that this is dispensable in the tumor microenvironment. (4) What is the level of 
Treg fragility and instability in checkpoint blockade responders and non-responders, and 
do they correlate? (5) Is Treg fragility a biomarker of patient response? and (6) Does 
patient response to immunotherapy depend on Treg fragility? Indeed, while loss of Nrp1 
and increased IFNγ sensitivity have been identified as drivers of Treg fragility, there may 
be other molecules that contribute to this phenotype that have yet to be defined. I 
propose that the development of combinatorial immunotherapies that maximize Treg 
















Stability and function of regulatory T cells is maintained by a neuropilin-1-
semaphorin-4a axis 
This is a collaborative project with many previous lab members and was published in 
Nature in 2013. I will introduce the primary observations with their permission as well as 
show data I generated in this appendix.  
Neuropilin-1 (Nrp1) is a surface receptor expressed by many cells types; 
however, it is highly upregulated on Tregs and has been previously shown to bind to 
Semaphorin 3a and VEGF49, 182. Dr. Creg Workman performed a microarray on 
stimulated Tregs and compared this transcriptome to Tconv transcripts to identify possible 
molecules provided by Tconv cells that boost Treg function. Sema4a was identified in this 
screen, and the lab reasoned that this may bind Nrp1 on Tregs and contribute to their 
function. In order to test this, the lab bred and used Nrp1L/LFoxp3Cre-YFP mice in which 
Nrp1 is selectively removed on Tregs but remains intact in all other cells. Interestingly, 
Nrp1L/LFoxp3Cre-YFP mice showed no autoimmune effects past one year of age, 
suggesting that Nrp1 is not required to maintain homeostatic Treg function. To test how 
Nrp1 may affect Tregs under inflammatory conditions, Drs. Greg Delgoffe and Meghan 
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Turnis injected Nrp1L/LFoxp3Cre-YFP, Foxp3Cre-YFP, and Foxp3DTR-GFP (in which Tregs are 
deleted upon diphtheria toxin administration) mice with a variety of transplantable tumor 
types, including B16 melanoma, MC38 adenocarcinoma, and EL4 thymoma. These 
tumor types were chosen because they are well characterized and have varying levels 
of aggressiveness and immunogenicity. While Foxp3DTR-GFP mice are resistant to tumor 
growth, the mice ultimately succumb to autoimmune effects shortly thereafter. In 
contrast, Nrp1L/LFoxp3Cre-YFP mice show equal tumor resistance without any 
autoimmunity (Fig. 26 A-C). Similarly, C57BL/6 mice treated with Sema4a antibody, 
Nrp1 antibody (does not block Nrp1:VEGF), or Sema4a-IgG1 (soluble antagonist), 





























Figure 26: Nrp1-deficient Treg cells fail to suppress anti-tumor immune responses 
Tumor growth curves and survival plots. (A) Foxp3Cre, Nrp1f/fFoxp3Cre, or Foxp3DTR-GFP mice received 
1.25 × 105 MC38 melanoma cells subcutaneously and (for Foxp3DTR-GFP) 100 µg diphtheria toxin (DT) 
intraperitoneally, twice weekly. (B) As in (A), but mice received 1.25 × 105 EL4 thymoma i.d. (C) As 
in (A), but mice received 1.25 × 105B16 melanoma i.d. (D) Tumor growth curve of C57/BL6 mice 
receiving 1.25 × 105B16 melanoma i.d. concomitant with injections of isotype control, anti-Sema4a, or 
anti-Nrp1 (100 µg) twice weekly. (E) Tumor growth curve as in (D) except mice received Sema4a-IgG1 
twice weekly. (F) Tumor growth curve of C57/BL6 mice receiving 1.25 × 105 B16 melanoma 
intradermally. When tumors were palpable (day 5, indicated by arrow), mice began receiving injections 
of anti-Nrp1 or its isotype control (400 µg initially, 200 µg every 3 days).  Results represent 3-5 
experiments. *p < 0.05, **p < 0.01, ***p< 0.001. One-way analysis of variance (ANOVA) was used. CR, 
complete response. Error bars indicate s.e.m 
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 Dr. Greg Delgoffe then took a variety of approaches to determine the signaling pathway 
downstream of Nrp1:Sema4a ligation. The Akt/mTOR pathway has previously been 
shown to be critical for Treg function (through restraining Akt signaling) and Nrp1 has 
been shown to modulate Akt activity. He further showed that pAKT was reduced upon 
Nrp1:Sema4a ligation in Tregs in a PTEN dependent manner. Given that Akt acts in part 
by preventing Foxo1/3a translocation to the nucleus, I sought to determine if this was 
the acting mechanism by which Nrp1 maintains Foxp3 stability. Indeed, Foxo1/3a 
nuclear translocation supports Foxp3 stability. Dr. Cliff Guy and myself found that 
Nrp1:Sema4a ligation supported Foxo1/3a nuclear translocation, as this was reduced in 
Tregs stimulated overnight in the absence of Sema4a and was rescued with the cells 








Figure 27: Ligation of Nrp1 by Sema4a promotes Treg-cell stability through modulation of Akt-
mTOR signaling 
Foxo3a nuclear (A) and cytoplasmic (B) localization signals, as defined by masking using actin and 
DNA staining. Arbitrary Units represent fluorescence intensity calculated volumetrically through 20 to 
30 slices of Treg cells. n = 70–93. US, unstimulated (control).  Results represent at least three 




Nrp1 supports Treg hypomethylation in the tumor microenvironment 
Foxp3 expression is the key characteristic of a stable Treg. While there are many factors 
that contribute to Foxp3 stability, lack of methylation at the locus is considered the 
primary one. Initially described as the Treg specific demethylated region (TSDR, later 
renamed the conserved non-coding sequence or CNS2), this locus consists of two 
regions: one upstream of the Foxp3 promoter and one in intron 7. CD4+ Tconv show 
almost 100% methylation at these sites while Tregs show dramatically reduced 
methylation in the Foxp3 promoter region while they maintain methylation in intron 7, 
suggesting that this hypomethylation pattern is specific rather than global or random 45. 
In addition, Treg development requires both Foxp3 and hypomethylation at the promoter 
48, and Treg stability is lost in the absence of the CNS2 locus 183. In order to determine 
whether Nrp1 was contributing to Treg stability through epigenetic regulation, I performed 
bisulfite sequencing on Tregs and Tconv isolated from ndLN and TIL of Foxp3Cre-YFP and 
Nrp1L/LFoxp3Cre-YFP mice. I hypothesized that Nrp1– Tregs would remain hypomethylation 
at the Foxp3 locus given that Foxp3 expression is not decreased in these cells, either 
by percentage or a per cell basis (MFI). Surprisingly, Nrp1–/– Tregs showed a striking 
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increase in methylation in the Foxp3 promoter locus compared to WT Tregs within the 








Figure 28: Nrp1-deficient Tregs are hypermethylated in the TME. 
Methylation Analysis on ndLN Teff and ndLN and TIL Tregs after bisulfite sequencing was performed on day 
12 post B16 tumor inoculation. 
 
There are two possibilities for this phenotype: 1) Nrp1–/– Tregs never become 
demethylated, possibly because of a reduction in TET proteins, or 2) Nrp1–/– Tregs 
become re-methylated due to changes in methyltransferases such as DNMT3a/b. TET 
proteins convert 5-methylcytosine to 5-hydroxymethylcytosine and are required for 
demethylation at the CNS2. When TET2/3 are removed from CD4+ T cells in mice 
through the use of a TET2/3L/LCD4Cre mouse, Foxp3 expression is reduced in the 
periphery, and TET2/3 DKO Tregs were unable to rescue RAG–/– mice, suggesting  a role 
for TET proteins in maintaining Treg stability 68, 184. In addition, Treg stability is maintained 
by downregulation of DNA methyltransferases (DNMTs) 66, 173. While more studies are 
required to determine the cause of hypermethylation at the Foxp3 promoter while 
maintaining Foxp3 expression, I hypothesize that modifications in DNMTs within the 
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tumor microenvironment lead to de novo re-methylation of the Foxp3 locus in the 
absence of Nrp1. Interestingly, reduction of DNMTs via 5-azacytidine treatment led to 
increased Nrp1 expression on pDCs, suggesting a relationship between methylation 
status and Nrp1-driven Treg stability; however, additional experiments dilineating 
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